Precigen (PGEN) 10-K 1 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Feb. 15, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Trading Symbol	XON
Entity Registrant Name	INTREXON CORP
Entity Central Index Key	1,356,090
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		160,408,958
Entity Public Float			$ 959.4

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 102,768	$ 68,111
Restricted cash	6,987	6,987
Short-term investments	119,688	6,273
Equity securities	384	5,285
Receivables
Trade, net	21,195	19,775
Related parties, net	4,129	17,913
Other, net	2,754	2,153
Inventory	21,447	20,493
Prepaid expenses and other	6,131	7,057
Total current assets	285,483	154,047
Equity securities, noncurrent	1,798	9,815
Investments in preferred stock	191	161,225
Property, plant and equipment, net	128,874	112,674
Intangible assets, net	129,291	232,877
Goodwill	149,585	153,289
Investments in affiliates	18,859	18,870
Other assets	2,096	4,054
Total assets	716,177	846,851
Current liabilities
Accounts payable	13,420	8,701
Accrued compensation and benefits	10,687	6,474
Other accrued liabilities	20,620	21,080
Deferred revenue, including $6,945 and $29,155 from related parties as of December 31, 2018 and 2017, respectively	15,554	42,870
Lines of credit	466	233
Current portion of long-term debt	559	502
Related party payables	256	313
Total current liabilities	61,562	80,173
Long-term debt, net of current portion, including $55,290 to related parties as of December 31, 2018	211,235	7,535
Deferred revenue, net of current portion, including $52,227 and $157,628 from related parties as of December 31, 2018 and 2017, respectively	54,210	193,527
Deferred tax liabilities, net	7,213	15,620
Other long-term liabilities	3,235	3,451
Total liabilities	337,455	300,306
Commitments and contingencies (Note 16)
Total equity
Common stock, no par value, 200,000,000 shares authorized as of December 31, 2018 and 2017; and 160,020,466 shares and 122,087,040 shares issued and outstanding as of December 31, 2018 and 2017, respectively	0	0
Additional paid-in capital	1,722,012	1,397,005
Accumulated deficit	(1,330,545)	(847,820)
Accumulated other comprehensive loss	(28,612)	(15,554)
Total Intrexon shareholders' equity	362,855	533,631
Noncontrolling interests	15,867	12,914
Total equity	378,722	546,545
Total liabilities and total equity	$ 716,177	$ 846,851

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Current portion of deferred revenue	$ 15,554	$ 42,870
Long-term debt, less current portion	211,235	7,535
Long-term portion of deferred revenue	$ 54,210	$ 193,527
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	160,020,466	122,087,040
Common stock, shares outstanding	160,020,466	122,087,040
Related Parties, Aggregated
Related Party Transaction [Line Items]
Current portion of deferred revenue	$ 6,945	$ 29,155
Long-term debt, less current portion	55,290
Long-term portion of deferred revenue	$ 52,227	$ 157,628

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues
Revenues	$ 160,574	$ 230,981	$ 190,926
Operating Expenses
Research and development	404,586	143,207	112,135
Selling, general and administrative	137,807	146,103	142,318
Impairment loss	60,504	16,773	0
Total operating expenses	666,184	368,871	316,092
Operating loss	(505,610)	(137,890)	(125,166)
Other Income (Expense), Net
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock	(30,200)	2,586	(58,894)
Interest expense	(8,530)	(611)	(861)
Interest and dividend income	19,084	19,485	10,190
Other income, net	630	1,013	1,700
Total other income (expense), net	(19,016)	22,473	(47,865)
Equity in net loss of affiliates	(11,608)	(14,283)	(21,120)
Loss before income taxes	(536,234)	(129,700)	(194,151)
Income tax benefit	21,528	2,880	3,877
Net loss	(514,706)	(126,820)	(190,274)
Net loss attributable to the noncontrolling interests	5,370	9,802	3,662
Net loss attributable to Intrexon	$ (509,336)	$ (117,018)	$ (186,612)
Net loss attributable to Intrexon per share, basic and diluted (in usd per share)	$ (3.93)	$ (0.98)	$ (1.58)
Weighted average shares outstanding, basic and diluted (in shares)	129,521,731	119,998,826	117,983,836
Collaborations and licenses
Revenues
Revenues	$ 76,869	$ 145,579	$ 109,871
Product
Revenues
Revenues	28,528	33,589	36,958
Operating Expenses
Cost of product and services	35,698	33,263	37,709
Service
Revenues
Revenues	52,419	50,611	43,049
Operating Expenses
Cost of product and services	27,589	29,525	23,930
Other
Revenues
Revenues	$ 2,758	$ 1,202	$ 1,048

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Revenues	$ 160,574	$ 230,981	$ 190,926
Collaborations and licenses
Related Party Transaction [Line Items]
Revenues	76,869	145,579	109,871
Collaborations and licenses | Related Parties, Aggregated
Related Party Transaction [Line Items]
Revenues	$ 60,238	$ 130,670	$ 93,792

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (514,706)	$ (126,820)	$ (190,274)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(59)	87	430
Gain (loss) on foreign currency translation adjustments	(13,073)	20,599	(23,901)
Comprehensive loss	(527,838)	(106,134)	(213,745)
Comprehensive loss attributable to the noncontrolling interests	5,548	9,764	3,683
Comprehensive loss attributable to Intrexon	$ (522,290)	$ (96,370)	$ (210,062)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' and Total Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Intrexon Shareholders' Equity	Noncontrolling Interests
Beginning balance at Dec. 31, 2015	$ 704,886	$ 0	$ 1,249,559	$ (12,752)	$ (542,729)	$ 694,078	$ 10,808
Beginning balance, shares at Dec. 31, 2015		116,658,886
Changes in Stockholders' Equity
Stock-based compensation expense	42,181		42,108			42,108	73
Exercises of stock options and warrants	19,165		19,165			19,165	0
Exercises of stock options and warrants, shares		1,400,146
Shares issued as payment for services	10,777		10,777			10,777	0
Shares issued as payment for services, shares		434,061
Shares and warrants issued in business combination	0
Shares issued in asset acquisition or for reacquired in-process research and development	4,401		4,401			4,401	0
Shares issued in asset acquisition or for reacquired in-process research and development, shares		136,340
Shares issued as payment for contingent or deferred consideration	1,583		1,583			1,583	0
Shares issued as payment for contingent or deferred consideration, shares		59,337
Acquisition of noncontrolling interest	0		(1,813)			(1,813)	1,813
Acquisition of noncontrolling interest, shares		0
Net loss	(190,274)				(186,612)	(186,612)	(3,662)
Other comprehensive income (loss)	(23,471)			(23,450)		(23,450)	(21)
Ending balance at Dec. 31, 2016	569,248	$ 0	1,325,780	(36,202)	(729,341)	560,237	9,011
Ending balance, shares at Dec. 31, 2016		118,688,770
Changes in Stockholders' Equity
Cumulative effect of adoption of new accounting standards	0		1,461		(1,461)	0	0
Stock-based compensation expense	41,576		41,525			41,525	51
Exercises of stock options and warrants	980		952			952	28
Exercises of stock options and warrants, shares		149,429
Shares issued as payment for services	11,118		11,118			11,118	0
Shares issued as payment for services, shares		654,456
Shares and warrants issued in public or private offerings, net of issuance costs	13,686		13,686			13,686	0
Shares issued in public or private offerings, net of issuance costs, shares		1,207,980
Shares and warrants issued in business combination	16,997		16,997			16,997	0
Shares issued in business combinations, shares		684,240
Shares issued as payment for contingent or deferred consideration	0		0			0	0
Shares issued as payment for contingent or deferred consideration, shares		480,422
Acquisition of noncontrolling interest	(913)		5,082			5,082	(5,995)
Adjustments for noncontrolling interests	(13)		2,789			2,789	(2,802)
Acquisition of noncontrolling interest, shares		221,743
Noncash dividend	0		(22,385)			(22,385)	22,385
Net loss	(126,820)				(117,018)	(117,018)	(9,802)
Other comprehensive income (loss)	20,686			20,648		20,648	38
Ending balance at Dec. 31, 2017	$ 546,545	$ 0	1,397,005	(15,554)	(847,820)	533,631	12,914
Ending balance, shares at Dec. 31, 2017	122,087,040	122,087,040
Changes in Stockholders' Equity
Cumulative effect of adoption of new accounting standards	$ 26,507		0	(104)	26,611	26,507	0
Stock-based compensation expense	36,296		36,174			36,174	122
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	2,336		297			297	2,039
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares		70,159
Shares issued as payment for services	10,695		10,695			10,695	0
Shares issued as payment for services, shares		909,980
Shares and warrants issued in public or private offerings, net of issuance costs	87,990		82,374			82,374	5,616
Shares issued in public or private offerings, net of issuance costs, shares		6,900,000
Equity component of convertible debt, net of issuance costs and deferred taxes	36,868		36,868			36,868	0
Shares issued pursuant to share lending agreement	0		0			0	0
Shares issued pursuant to share lending agreement, shares		7,479,431
Shares and warrants issued in business combination	0
Shares issued in asset acquisition or for reacquired in-process research and development	159,323		159,323			159,323	0
Shares issued in asset acquisition or for reacquired in-process research and development, shares		22,573,856
Shares issued as payment for contingent or deferred consideration	0
Adjustments for noncontrolling interests	0		(724)			(724)	724
Net loss	(514,706)				(509,336)	(509,336)	(5,370)
Other comprehensive income (loss)	(13,132)			(12,954)		(12,954)	(178)
Ending balance at Dec. 31, 2018	$ 378,722	$ 0	$ 1,722,012	$ (28,612)	$ (1,330,545)	$ 362,855	$ 15,867
Ending balance, shares at Dec. 31, 2018	160,020,466	160,020,466

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (514,706)	$ (126,820)	$ (190,274)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	33,112	31,145	24,572
Loss on abandonment and disposal of assets, net	20,928	3,124	666
Impairment loss	60,504	16,773	0
Reacquisition of in-process research and development	236,748	0	0
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net	30,200	(2,586)	58,894
Noncash dividend income	(14,841)	(16,756)	(7,421)
Amortization of premiums (discounts) on investments, net	(771)	411	1,070
Equity in net loss of affiliates	11,608	14,283	21,120
Stock-based compensation expense	36,296	41,576	42,202
Shares issued as payment for services	10,695	11,118	10,777
Provision for bad debts	1,779	1,217	1,963
Accretion of debt discount and amortization of deferred financing costs	4,378	0	0
Deferred income taxes	(21,278)	(2,528)	(3,467)
Other noncash items	1,093	(517)	1,662
Receivables:
Trade	(2,698)	740	2,588
Related parties	11,003	631	6,804
Notes	0	0	(42)
Other	(542)	661	271
Inventory	(478)	663	3,807
Prepaid expenses and other	1,006	492	(932)
Other assets	652	(1,017)	2,189
Accounts payable	4,680	(3,402)	3,618
Accrued compensation and benefits	4,385	(1,466)	(12,402)
Other accrued liabilities	356	3,007	9,002
Deferred revenue	(38,578)	(75,337)	(25,481)
Deferred consideration	0	(313)	(630)
Related party payables	(52)	(147)	310
Other long-term liabilities	281	1,328	146
Net cash used in operating activities	(124,240)	(103,720)	(48,988)
Cash flows from investing activities
Purchases of investments	(178,681)	0	(75,246)
Maturities of investments	65,975	174,542	101,987
Purchases of equity securities, preferred stock, and warrants	0	(1,161)	(2,308)
Proceeds from sales of equity securities	217	235	280
Acquisitions of businesses, net of cash received	(920)	2,054	0
Investments in affiliates	(16,582)	(11,189)	(11,542)
Return of investment in affiliate	2,598	0	0
Cash received (paid) in asset acquisitions	15,500	(14,219)	(7,244)
Purchases of property, plant and equipment	(41,587)	(46,666)	(31,629)
Proceeds from sale of assets	2,267	1,636	274
Issuances of notes receivable	0	(2,400)	(2,964)
Proceeds from repayment of notes receivable	0	1,500	0
Net cash provided by (used in) investing activities	(151,213)	104,332	(28,392)
Cash flows from financing activities
Proceeds from issuance of shares in a private placement	0	13,686	0
Proceeds from issuance of shares and warrants in public offerings, net of issuance costs	87,990	0	0
Acquisitions of noncontrolling interests	0	(913)	0
Advances from lines of credit	4,561	5,906	5,075
Repayments of advances from lines of credit	(4,328)	(6,493)	(4,816)
Proceeds from long-term debt, net of issuance costs	219,859	325	547
Payments of long-term debt	(623)	(519)	(1,201)
Payments of deferred consideration for acquisitions	0	(8,678)	(6,705)
Proceeds from stock option and warrant exercises	2,336	980	19,165
Payment of stock issuance costs	0	(10)	0
Net cash provided by financing activities	309,795	4,284	12,065
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	295	1,055	(873)
Net increase (decrease) in cash, cash equivalents, and restricted cash	34,637	5,951	(66,188)
Cash, cash equivalents, and restricted cash
Beginning of period	75,545	69,594	135,782
End of period	102,768	68,111
Supplemental disclosure of cash flow information
Cash paid during the period for interest	3,868	617	964
Cash paid during the period for income taxes	216	566	10
Significant noncash financing and investing activities
Stock received as consideration for collaboration agreements	0	0	18,766
Preferred stock received as consideration for collaboration amendments	0	0	120,000
Receivables converted to preferred stock	0	3,385	0
Stock and warrants issued in business combinations	0	16,997	0
Stock issued to acquire noncontrolling interests	0	5,082	0
Stock issued for reacquired in-process research and development	159,323	0	0
Stock issued in asset acquisition	0	0	4,401
Long-term debt issued to a related party in an asset acquisition	30,000	0	0
Contingent consideration assumed in asset acquisition	0	0	3,660
Stock issued as payment for contingent consideration	0	0	1,583
Noncash dividend to shareholders	0	22,385	0
Purchases of property and equipment included in accounts payable and other accrued liabilities	2,267	2,257	652
Purchases of equipment financed through debt	234	0	0
Receivable recorded in anticipation of dissolution of affiliate	0	2,598	0
Transfer of inventory to breeding stock	$ 0	$ 0	$ 1,191

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Reconciliation of Cash) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 102,768	$ 68,111
Restricted cash	6,987	6,987
Restricted cash included in other assets	427	447
Cash, cash equivalents, and restricted cash	$ 110,182	$ 75,545

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Intrexon Corporation ("Intrexon"), a Virginia corporation, uses synthetic biology to focus on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals, which may be accomplished directly or through collaborations and joint ventures. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Hungary. There have been no commercialized products derived from Intrexon's collaborations to date. Precigen, Inc. ("Precigen"), a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases, is a wholly owned subsidiary of Intrexon with primary operations in Maryland. ActoBio Therapeutics, Inc. ("ActoBio") is pioneering a new class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Intrexon with primary operations in Belgium. Trans Ova Genetics, L.C. ("Trans Ova"), and Progentus, L.C. ("Progentus"), providers of advanced reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in Iowa, Maryland, Missouri, New York, Oklahoma, and Texas. ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, is a wholly owned subsidiary of Trans Ova with primary operations in Iowa. Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil. Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company that developed and received regulatory approval for the world's first non-browning apple without the use of any artificial additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington. Exemplar Genetics, LLC ("Exemplar") is a provider of genetically engineered swine for medical and genetic research and a wholly owned subsidiary with primary operations in Iowa. As of December 31, 2018 , Intrexon owned approximately 55% of AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture, and whose common stock is listed on the NASDAQ Stock Market. See Note 14 for additional discussion. Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company." These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP"). Liquidity and Going Concern The Company has incurred operating losses since its inception and management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. As of December 31, 2018 , the Company had $222,456 in cash, cash equivalents and short-term investments which is not sufficient to fund the Company's planned operations through one year after the date the consolidated financial statements are issued and accordingly, there is substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern does not include cash sources outside of the Company's direct control that management expects to be available within the next twelve months. The Company may not be able to obtain sufficient additional funding through monetizing certain of its existing assets, entering into new license and collaboration agreements, issuing additional equity or debt instruments or any other means, and if it is able to do so, they may not be on satisfactory terms. The Company's ability to raise additional capital in the equity and debt markets, should the Company choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Should the Company not be able to secure additional funding though these means, the Company may have to engage in any or all of the following activities: (i) shift internal investments from subsidiaries and platforms whose potential for value creation is longer-term to near-term opportunities; (ii) sell certain of our operating subsidiaries to third parties; (iii) reduce operating expenditures for third-party contractors, including consultants, professional advisors and other vendors; and (iv) reduce or delay capital expenditures, including non-essential facility expansions, lab equipment, and information technology projects. These actions may have a material adverse impact on the Company's ability to achieve certain of its planned objectives. Even if the Company is able to source additional funding, it may be forced to significantly reduce its operations if its business prospects do not improve. If the Company is unable to source additional funding, it may be forced to shut down operations altogether. These consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event the Company can no longer continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated. Revenue Recognition (For the Year Ended December 31, 2018) Effective January 1, 2018, the Company applies Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations. Collaboration and licensing revenues The Company generates collaboration and licensing revenues through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement; (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities; and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days . The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and in certain cases manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement. At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606. The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate. As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company. From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue. Product and service revenues The Company generates product and service revenues primarily through sales of products and services that are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days . Revenue Recognition (For the Years Ended December 31, 2017 and 2016) Collaboration and licensing revenues The Company generates collaboration and licensing revenue through collaboration and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement. Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations, which is reevaluated each reporting period. The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria: (1) The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone; (2) The consideration relates solely to past performance; and (3) The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments. Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned. From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue. Product and service revenues The Company generates product and service revenues primarily through sales of products and services that are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured. Research and Development The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in research and development. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses. The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December 31, 2018 and 2017 , the Company had research and development commitments with third parties that had not yet been incurred totaling $11,853 and $10,682 , respectively. The commitments are generally cancellable by the Company at any time upon written notice. Cash and Cash Equivalents All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer. As of December 31, 2018 and 2017 , the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $40,155 and $43,012 , respectively. Restricted Cash Restricted cash represents funds deposited with the United States Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 16 ). Short-term and Long-term Investments As of December 31, 2018 , short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard & Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer. Equity Securities The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statements of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. Equity securities that the Company does not intend to sell within one year are classified as noncurrent in the consolidated balance sheet. The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter. Investments in Preferred Stock The Company holds preferred stock in certain of its collaborators, most of which may be converted to common stock as described in Note 7 . The Company elected the fair value option to account for its investments in preferred stock whereby the value of preferred stock is adjusted to fair value as of each reporting date and unrealized gains and losses are reported in the consolidated statements of operations. These investments are subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of certain of the preferred stock into common stock, the volatility of each collaborator's common stock, and changes in general economic and financial conditions of the collaborators. The investments are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell the investments nor expect the investments that are convertible into common stock to be converted within one year. The Company is entitled to monthly dividends and records dividend income as described in Note 7 . Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1: Quoted prices in active markets for identical assets and liabilities; Level 2: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available. Concentrations of Risk Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2018 , gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable. Equity Method Investments The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note 17 ) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Note 3 . The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators and a related party, using the fair value option. Oragenics was considered an equity method investment until September 30, 2018, by which point the Company's ownership level had significantly decreased. See Note 7 for additional discussion regarding Oragenics. The Company's ownership of Oragenics was 29.4% as of December 31, 2017 , and the fair value of the Company's investment was $3,085 as of that date, which is included as equity securities, noncurrent, in the accompanying consolidated balance sheet. Unrealized depreciation in the fair value of these securities was $4,159 and $10,523 for the years ended December 31, 2017 and 2016 , respectively. Summarized financial data as of December 31, 2018 and 2017 , and for the years ended December 31, 2018 , 2017 , and 2016 , for the Company's equity method investments are shown in the following tables. December 31, 2018 2017 Current assets $ 17,485 $ 61,086 Noncurrent assets 31,274 13,598 Total assets 48,759 74,684 Current liabilities 4,226 6,213 Net assets $ 44,533 $ 68,471 Year Ended December 31, 2018 2017 2016 Revenues $ 557 $ 254 $ 417 Operating expenses 36,990 41,904 62,373 Operating loss (36,433 ) (41,650 ) (61,956 ) Other, net 44 (8 ) 1,535 Net loss $ (36,389 ) $ (41,658 ) $ (60,421 ) Variable Interest Entities The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. As of December 31, 2018 and 2017 , the Company determined that certain of its collaborators and joint ventures as well as Harvest were VIEs. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of December 31, 2018 and 2017 , were $21,219 and $185,261 , respectively, which represents the Company's maximum risk of loss related to the identified VIEs. Trade Receivables Trade receivables consist of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts. The following table shows the activity in the allowance for doubtful receivable accounts for the years ended December 31, 2018 , 2017 , and 2016 : 2018 2017 2016 Beginning balance $ 4,631 $ 3,703 $ 2,081 Charged to operating expenses 1,779 1,217 1,963 Write offs of accounts receivable, net of recoveries (1,267 ) (289 ) (341 ) Ending balance $ 5,143 $ 4,631 $ 3,703 Inventory The Company's inventory primarily includes adult female cows that are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows: Years Land improvements 4–20 Buildings and building improvements 3–25 Furniture and fixtures 1–10 Equipment 1–10 Breeding stock 1–4 Computer hardware and software 1–7 Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to twenty years . Goodwill Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the goodwill impairment test is not required. If the goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary. The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review. In the fourth quarter of 2018, the Company concluded that Precigen and ActoBio are now separate reporting units. Accordingly, the Company performed a relative fair value allocation of certain of its goodwill, as well as an impairment review of the reallocated goodwill. See Note 11 for additional discussion regarding the results of this review for the year ended December 31, 2017, which resulted in a goodwill impairment charge. Intangible Assets Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development technologies acquired in mergers or acquisitions and were recorded at fair value at the dates of the respective acquisitions. The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from three to twenty-one years for the patents, developed technologies and know-how; customer relationships; and trademarks. Impairment of Long-Lived Assets Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manne

Mergers and Acquisitions

Mergers and Acquisitions	12 Months Ended
	Dec. 31, 2018
Mergers and Acquisitions [Abstract]
Mergers and Acquisitions	Mergers and Acquisitions Asset Acquisition of Certain Harvest Entities In September 2018, the Company, through its wholly owned subsidiary ActoBio, issued $30,000 of convertible promissory notes to Harvest, a related party, to acquire Harvest's ownership in CRS Bio, Inc. ("CRS Bio"); Genten Therapeutics, Inc. ("Genten Therapeutics"); and Relieve Genetics, Inc. ("Relieve Genetics") (collectively the "Harvest entities") (Note 17 ). The Company also received $15,500 cash in the transaction from the acquisition of the Harvest entities. Prior to the transaction, the Company held a noncontrolling interest in the Harvest entities, with a combined carrying value for all entities of $4,303 , and accounted for its ownership using the equity method of accounting. Following the transaction, the Company owns 100% of the equity interests of the Harvest entities including the rights that had been previously licensed to the Harvest entities by the Company. The Harvest entities did not meet the definition of a business and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to the Harvest entities, the Company is relieved from its obligations under the original ECCs and therefore wrote off deferred revenue of $10,078 as part of the transaction. The remaining value acquired of $8,721 was considered in-process research and development related to the reacquired rights under the ECCs and expensed immediately. See Note 12 for additional discussion of the convertible promissory notes. GenVec Acquisition In June 2017, pursuant to an Agreement and Plan of Merger (the "GenVec Merger Agreement"), the Company acquired 100% of the outstanding shares of GenVec, Inc. ("GenVec"), a clinical-stage company and pioneer in the development of AdenoVerse gene delivery technology. Pursuant to the GenVec Merger Agreement, the former shareholders of GenVec received an aggregate of 684,240 shares of the Company's common stock and have the right to receive contingent consideration equal to 50% of any milestone or royalty payments received under one of GenVec's collaboration agreements, provided such payments are received within three years after the closing of the transaction. The Company also assumed warrants held by certain former shareholders of GenVec. The results of GenVec's operations subsequent to the acquisition date have been included in the consolidated financial statements. The fair value of the total consideration transferred was $17,582 . The acquisition date fair value of each class of consideration transferred is presented below: Common shares $ 15,616 Warrants 1,381 Contingent consideration 585 $ 17,582 The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock immediately prior to the closing of the acquisition. The fair value of the warrants assumed was estimated using the Black-Scholes option-pricing model. The fair value of the contingent consideration was determined using a probability weighted discounted cash flows model and is considered a freestanding financial instrument and recorded at fair value each reporting period. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below: Cash and cash equivalents $ 2,054 Short-term investments 542 Trade receivables 75 Other receivables 97 Prepaid expenses and other 227 Property and equipment 250 Intangible assets 14,000 Other noncurrent assets 58 Total assets acquired 17,303 Accounts payable 2,158 Accrued compensation and benefits 1,226 Other accrued expenses 856 Other long-term liabilities 92 Deferred tax liabilities 239 Total liabilities assumed 4,571 Net assets acquired 12,732 Goodwill 4,850 Total consideration $ 17,582 The acquired intangible assets include developed technology, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The intangible assets are being amortized over a useful life of eleven years . Goodwill, which is not deductible for tax purposes, represents the assembled workforce and the anticipated buyer-specific synergies arising from the combination of the Company's and GenVec's technology. Acquisition-related costs totaling $ 507 and $ 12 are included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the years ended December 31, 2017 and 2016 , respectively. Unaudited Condensed Pro Forma Financial Information GenVec's results of operations subsequent to the acquisition are included in the consolidated statements of operations. The following unaudited condensed pro forma financial information for the years ended December 31, 2017 and 2016, is presented as if the acquisition had been consummated on January 1, 2016: Year Ended December 31, 2017 2016 Pro Forma Revenues $ 231,213 $ 191,437 Loss before income taxes (136,966 ) (201,210 ) Net loss (134,275 ) (197,144 ) Net loss attributable to the noncontrolling interests 9,802 3,662 Net loss attributable to Intrexon (124,473 ) (193,482 )

Investments in Joint Ventures

Investments in Joint Ventures	12 Months Ended
	Dec. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's methane bioconversion platform ("MBP") technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50% . In addition, Intrexon has committed to make capital contributions of up to $25,000 , and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000 , at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of December 31, 2018 , the Company's remaining commitment was $4,938 . Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(656) and $(444) as of December 31, 2018 and 2017 , respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50% . In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000 , half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000 , and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000 , at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(50) and $572 as of December 31, 2018 and 2017 , respectively, and is included in other accrued liabilities and investments in affiliates, respectively, in the accompanying consolidated balance sheets. EnviroFlight In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). The Company determined that the series of integrated transactions to acquire substantially all of the assets of Old EnviroFlight for cash, common stock, and contingent consideration should be accounted for as a single transaction, which constituted a business, and considered New EnviroFlight to be the accounting acquirer. Consideration paid to Old EnviroFlight was $4,244 in cash, 136,340 shares of the Company's common stock valued at $4,401 and contingent consideration estimated at $3,660 . Contemporaneously, all the assets acquired from Old EnviroFlight, with the exception of certain developed technology, and $3,000 of cash were contributed to New EnviroFlight in exchange for a non-controlling, 50% membership interest in New EnviroFlight. The Company's contributions to New EnviroFlight included an exclusive license to the developed technology that was retained by the Company. Darling received the remaining 50% membership interest in New EnviroFlight as consideration for terminating rights previously held in the developed technology with Old EnviroFlight. New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products, from black soldier fly larvae. Through December 31, 2018 , both the Company and Darling have made subsequent capital contributions of $17,000 . All of the employees of Old EnviroFlight became employees of New EnviroFlight. The Company determined that its investment in New EnviroFlight should be accounted for using the equity method of accounting. The Company recorded an estimated fair value of $5,425 for its investment in New EnviroFlight and $9,880 for the retained developed technology intangible asset. The developed technology is being amortized over a period of twenty-one years . The contingent consideration liability payable to the members of Old EnviroFlight is considered a freestanding financial instrument and is recorded at fair value each reporting period. New EnviroFlight met a regulatory milestone, as defined in the asset purchase agreement, and the members of Old EnviroFlight received a portion of the contingent consideration consisting of 59,337 shares of the Company's common stock valued at $1,583 in October 2016. The members of Old EnviroFlight had a right to receive up to $4,000 of additional shares of the Company's common stock if certain commercial milestones were met prior to February 2019. No liability was recorded as of December 31, 2018 (Note 8 ), and these commercial milestones were not met prior to February 2019. The Company's investment in New EnviroFlight was $16,720 and $7,092 as of December 31, 2018 and 2017 , respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets. Intrexon T1D Partners In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners that provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50% . Intrexon committed to make capital contributions of up to $5,000 , and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, committed to make additional capital contributions of up to $5,000 , at the request of Intrexon T1D Partners' board of managers, which consisted of two members appointed by the Company and three members appointed by a majority of the T1D Investors. The Company satisfied its commitment in 2018. In November 2018, the Company, together with its wholly owned subsidiary ActoBio, issued 1,933,737 shares of Intrexon common stock valued at $18,970 to the T1D Investors to acquire their ownership interest in Intrexon T1D Partners. Following the transaction, the Company owns 100% of the membership interests in Intrexon T1D Partners, including the rights that had been previously licensed to Intrexon T1D Partners by the Company in the ECC. Intrexon T1D Partners did not meet the definition of a business, and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to Intrexon T1D Partners, the Company was relieved from its obligations under the original ECC and therefore wrote off $8,517 of deferred revenue as part of the transaction. The remaining value of $10,453 was considered in-process research and development related to the reacquired rights under the ECC and expensed immediately. Other Joint Ventures In December 2013, the Company and OvaScience, Inc. ("OvaScience") formed a joint venture, OvaXon, LLC ("OvaXon"). Additionally, the Company entered into separate ECC agreements with OvaXon and OvaScience. In March 2018, the Company and OvaScience agreed to terminate the ECC agreement with OvaScience. The Company and Millendo Therapeutics, Inc., a company that subsequently acquired OvaScience, are in discussions regarding the future of the OvaXon joint venture and the related ECC agreement. In September 2013, the Company and Sun Pharmaceutical Industries, Inc. ("Sun Pharmaceutical Industries") formed a joint venture, S & I Ophthalmic, LLC ("S & I Ophthalmic"), which entered into an ECC agreement with the Company. In December 2017, both the Company and Sun Pharmaceutical Industries agreed to dissolve S & I Ophthalmic and terminate the related ECC agreement. In January 2018, the Company received $2,598 upon the dissolution of S & I Ophthalmic, which represented the Company's portion of S & I Ophthalmic's remaining cash after all liabilities were settled.

Collaboration and Licensing Rev

Collaboration and Licensing Revenue	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Revenue	Collaboration and Licensing Revenue The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. At contract inception, the transaction price is typically the upfront payment received and is allocated to the single performance obligation. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. Amounts for periods subsequent to January 1, 2018 reflect revenue recognition under ASC 606. The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2018 , 2017 and 2016 . Year Ended December 31, 2018 2017 2016 ZIOPHARM Oncology, Inc. $ 16,298 $ 69,812 $ 33,836 Ares Trading S.A. 11,175 10,738 10,192 Oragenics, Inc. 1,353 2,020 2,752 Intrexon T1D Partners, LLC 2,502 5,968 1,908 Intrexon Energy Partners, LLC 6,929 10,665 17,552 Intrexon Energy Partners II, LLC 2,998 3,672 3,169 Genopaver, LLC 3,710 6,690 6,117 Fibrocell Science, Inc. 1,394 7,344 5,942 Persea Bio, LLC 955 946 1,278 OvaXon, LLC — 1,966 2,934 S & I Ophthalmic, LLC — 755 6,141 Harvest start-up entities (1) 14,447 15,232 4,974 Other 15,108 9,771 13,076 Total $ 76,869 $ 145,579 $ 109,871 (1) For the years ended December 31, 2018 , 2017 , and 2016 , revenue recognized from collaborations with Harvest start-up entities include Genten Therapeutics, Inc.; CRS Bio, Inc.; Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. For the years ended December 31, 2017 and 2016 , revenue recognized from collaborations with Harvest start-up entities also include Relieve Genetics, Inc. The following is a summary of the terms of the Company's significant collaborations and licensing agreements. ZIOPHARM Collaborations In January 2011, the Company entered into an ECC with ZIOPHARM Oncology, Inc. ("ZIOPHARM"), a related party at the time. Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform within the field of oncology as defined more specifically in the agreement. Upon execution of the ECC, the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $17,457 as upfront consideration. In addition to the promises discussed above, the Company transferred two clinical product candidates to ZIOPHARM for which $1,115 of the upfront consideration was allocated and recognized as collaboration revenue in 2011. The remaining $16,342 of upfront consideration was allocated to a single performance obligation as discussed above. The Company was entitled to additional shares of common stock at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by ZIOPHARM using the Company's technology ("ZIOPHARM Milestone"). In October 2012, the ZIOPHARM Milestone was achieved and the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $18,330 as milestone consideration. Upon adoption of ASC 606, the Company recorded a cumulative catch-up adjustment of $873 related to milestone consideration. The Company allocated the ZIOPHARM Milestone to the two performance obligations and recognized those in a manner similar to the discussion above. The Company received reimbursement payments for research and development services provided and manufacturing services for Company materials provided to ZIOPHARM during the ECC. In March 2015, in conjunction with the worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a wholly owned subsidiary of Merck KGaA, and ZIOPHARM discussed below, the Company and ZIOPHARM amended their existing ECC. The amendment modified the scope of the ECC in connection with the Merck Agreement and provided that the Company would pay to ZIOPHARM 50% of all payments received for upfront fees, milestones and royalties under the Merck Agreement. See discussion of the Merck Agreement below. In September 2015, the Company entered into its second ECC with ZIOPHARM ("ZIOPHARM ECC 2"). Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform to develop and commercialize novel biotherapeutics for the treatment of patients with graft-versus-host disease, or GvHD. Upon execution of ZIOPHARM ECC 2, the Company received a technology access fee of $10,000 . The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to ZIOPHARM during the ECC. In December 2017, the Company and ZIOPHARM mutually agreed to terminate ZIOPHARM ECC2 and accordingly, the Company recognized the remaining balance of the deferred revenue associated with ZIOPHARM ECC2 totaling $28,943 . In June 2016, the Company amended each of its two existing collaboration agreements with ZIOPHARM and as a result the rate of the royalty that the Company is entitled to receive on certain products commercialized pursuant to the agreements was reduced from 50% to 20% . As consideration for execution of the amendments, ZIOPHARM issued the Company 100,000 shares of ZIOPHARM's Series 1 Preferred Stock valued at $120,000 . The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. Upon adoption of ASC 606, the Company recognized a cumulative catch-up adjustment of $32,422 as a result of the contract modification requiring a cumulative catch-up under ASC 606 versus prospective recognition under previous revenue recognition accounting standards. See Note 7 for additional discussion of the terms of the preferred stock and the accounting treatment. In October 2018, the Company, through its wholly owned subsidiary Precigen, entered into a license agreement (the "ZIOPHARM License Agreement") with ZIOPHARM, which terminated and replaced the terms of the original ZIOPHARM ECC, including the amendments thereto. Pursuant to the terms of the ZIOPHARM License Agreement, the Company granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i) products utilizing the Company's RheoSwitch gene switch ("RTS") to express IL-12 (the "IL-12 Products") for the treatment of cancer, (ii) chimeric antigen receptor ("CAR") products directed to (a) CD19 for the treatment of cancer (the "CD19 Products"), and (b) a second target, subject to the rights of the Company to pursue such target under the Merck Agreement, and (iii) T-cell receptor ("TCR") products (the "TCR Products") designed for neoantigens for the treatment of cancer or the treatment and prevention of human papilloma virus ("HPV") to the extent that the primary reason for such treatment or prevention is to prevent cancer, which is referred to as the HPV Field. The Company has also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Company's Sleeping Beauty technology to research, develop and commercialize TCR Products for both neoantigens and shared antigens for the treatment of cancer and in the HPV Field. ZIOPHARM will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. ZIOPHARM is required to use commercially reasonable efforts to develop and commercialize IL-12 Products and CD19 Products, and after a two -year period, the TCR Products. The Company also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 (the "Gorilla IL-12 Products") for the treatment of cancer and in the HPV Field. ZIOPHARM is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. ZIOPHARM and the Company will share the development costs and operating profits for Gorilla IL-12 Products, with ZIOPHARM responsible for 80% of the development costs and receiving 80% of the operating profits, as defined in the ZIOPHARM License Agreement, and the Company responsible for the remaining 20% of the development costs and receiving 20% of the operating profits, except that ZIOPHARM will bear all development costs and the Company will share equally in operating profits for Gorilla IL-12 Products in the HPV Field (the "Gorilla Program"). In consideration of the licenses and other rights granted by the Company, ZIOPHARM will pay the Company an annual license fee of $100 and agreed to reimburse the Company $1,000 , payable in four quarterly installments, with respect to historical Gorilla IL-12 Products (the "historical Gorilla reimbursements"). ZIOPHARM will make milestone payments, payable upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions, totaling up to an additional $52,500 for each of four exclusively licensed products, up to an aggregate of $210,000 . In addition, ZIOPHARM will pay the Company tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sales of any approved IL-12 Products and CAR products. ZIOPHARM will also pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR Products, up to maximum royalty amount of $100,000 in the aggregate. ZIOPHARM will also pay the Company 20% of any sublicensing income received by ZIOPHARM relating to the licensed products. The Company reacquired rights to research, develop and commercialize CAR products for all other targets. In addition, the Company may research, develop and commercialize products for the treatment of cancer, outside of the products exclusively licensed to ZIOPHARM. The Company will pay ZIOPHARM royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of the Company's CAR products, up to $50,000 . The Company will also be entitled to receive from ZIOPHARM reimbursement of costs incurred to transition the necessary knowledge and materials for ZIOPHARM programs for a period of up to one year from the effective date (the "Transition Services"). As between the parties, the Company agreed to perform all of the obligations of ZIOPHARM under the Merck Agreement, other than an obligation of exclusivity thereunder and ZIOPHARM will remain responsible for all payments owed under the Merck Agreement with respect to CD19 and the other target under the Merck Agreement as a result of ZIOPHARM's, its affiliates' or its sublicensees' exploitation of CAR products. Further, the Company is entitled to receive all rights and financial considerations with respect to all other CAR products, subject to the CAR royalties due to ZIOPHARM for such products. The ZIOPHARM License Agreement will terminate on a product-by-product and/or country-by-country basis upon the expiration of the later to occur of (i) the expiration of the last to expire patent claim for a licensed product, or (ii) 12 years after the first commercial sale of a licensed product in such country. In addition, ZIOPHARM may terminate the ZIOPHARM License Agreement on a country-by-country or program-by-program basis following written notice to the Company, and either party may terminate the ZIOPHARM License Agreement following notice of a material breach. Pursuant to the ZIOPHARM License Agreement, the 2016 Securities Issuance Agreement between the Company and ZIOPHARM was terminated as of the effective date of the ZIOPHARM License Agreement, all of the benefits, rights, obligations and liabilities thereunder immediately ceased and terminated and the Company returned to ZIOPHARM all of the preferred stock owned by the Company as of the Effective Date, which was valued at $158,376 . See Note 7 for additional discussion of the preferred stock. Prior to the execution of the ZIOPHARM License Agreement, the Company had $51,084 of deferred revenue remaining from the original ECC, which was related to the Company's obligations to perform under that agreement. Replacement of the original ECC with the ZIOPHARM License Agreement is a contract modification under ASC 606 that represents the termination of the original agreement and the creation of a new agreement as the remaining rights, obligations, and services to be exchanged, which are limited to the Transition Services, are distinct from those under the ECC. Therefore, the Company reviewed the various forms of consideration in the ZIOPHARM License Agreement to determine the transaction price. As the Company's obligations under the ZIOPHARM License Agreement are only related to the Transition Services and no other obligations under the ECC remain, a portion of the previously deferred revenue from the ECC should be relieved, which the Company determined to be $49,329 , and the remaining $1,755 was included in the transaction price. The initial annual license payment of $100 was also included in the transaction price. The remaining annual license payments and potential milestone payments were constrained at the modification date and will only be recognized when the payments become probable of being received. Royalty payments from sales of ZIOPHARM products developed pursuant to the ZIOPHARM License Agreement will be recognized when the sales occur. The Company will recognize payments from Transition Services as those services are performed and will recognize the transaction price of $1,855 as it performs the Transition Services required under the ZIOPHARM License Agreement. The Company also reviewed the consideration paid and potential consideration to be paid to ZIOPHARM as part of the ZIOPHARM License Agreement, which includes the $158,376 of ZIOPHARM preferred stock returned by the Company and potential royalty payments to ZIOPHARM from sales of the Company's CAR products. The Company determined the exchange of its investment in ZIOPHARM preferred stock for certain CAR rights previously licensed under the ECC (i.e., in-process research and development) and the relief of performance obligations to ZIOPHARM under the ECC constituted an exchange for distinct goods and services. Therefore, the Company wrote off the $49,329 of relieved deferred revenue and recorded an expense of $109,047 for the reacquired in-process research and development. Potential royalty payments to ZIOPHARM will be expensed as incurred as they relate to distinct goods or services. The Company determined that the Gorilla Program represents a separate collaboration agreement under the scope of ASC 808, Collaborative Arrangements, ("ASC 808") and will not be included in the accounting for the ZIOPHARM License Agreement under ASC 606. The Company recognized $500 of the historical Gorilla reimbursements on the contract modification date and will recognize the remaining amounts when receipt is probable. The development costs and operating profits from the Gorilla Program will be recognized in accordance with ASC 808. Merck Licensing Agreement In March 2015, the Company signed the Merck Agreement with Ares Trading and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $115,000 as upfront consideration, of which $57,500 was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first two targets by Ares Trading, the Company received $10,000 in equal quarterly installments over two years. In December 2018, the Company entered into a Securities Purchase, Assignment and Assumption Agreement (the "Merck Purchase Agreement") with Ares Trading pursuant to which the Company reacquired Ares Trading's development and commercialization rights under the Merck Agreement. As consideration for the reacquisition of the Merck Agreement, the Company issued Ares Trading 20,640,119 shares of Intrexon common stock valued at $140,353 and agreed to pay Ares Trading a royalty of 10% of the net sales derived from two CAR products specified in the Merck Purchase Agreement. By reacquiring the rights previously licensed to Ares Trading, the Company is relieved of its obligations under the Merck Agreement and therefore wrote off deferred revenue of $31,826 . The remaining value acquired of $108,527 was considered in-process research and development related to the reacquired rights under the Merck Agreement and expensed immediately. The potential future royalty payments to Ares Trading do not represent consideration paid to a customer and will be recorded when the payments are probable. See Note 12 for additional discussion of this transaction. Oragenics Collaborations In June 2012, the Company entered into an ECC with Oragenics, a publicly traded company focused on becoming the world leader in novel antibiotics against infectious diseases and a related party. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of lantibiotics for the treatment of infectious diseases in humans and companion animals as defined more specifically in the agreement. Upon execution of the ECC, the Company received a technology access fee of 439,243 shares of Oragenics' common stock valued at $6,588 as upfront consideration. In November 2017, the Company amended the ECC agreement with Oragenics, and as a result, the Company is entitled to up to $35,000 of potential one-time payments for certain regulatory milestones. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. Oragenics will pay the Company 25% of the quarterly profits derived from the sale of products developed from the ECC, as defined in the agreement. Oragenics is responsible for funding the further development of lantibiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced in June 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company. In June 2015, the Company entered into a separate ECC with Oragenics ("Oragenics ECC 2"). Pursuant to Oragenics ECC 2, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of Oragenics ECC 2, the Company received a technology access fee of a $5,000 convertible promissory note maturing on or before December 31, 2015 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics' common stock, subject to its shareholders' approval. In December 2015, Oragenics converted the promissory note into 338,100 shares of Oragenics' common stock. Following an amendment in November 2017, the Company is entitled to up to $37,500 of potential one-time payments for development and commercial milestones under Oragenics ECC 2. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during Oragenics ECC 2 and manufacturing services for Company materials provided to Oragenics during Oragenics ECC 2. Oragenics will pay the Company royalties as a percentage in the low-teens of net sales derived from the sale of products developed from Oragenics ECC 2, as defined in the agreement. Oragenics is responsible for funding the further development of Oragenics ECC 2 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced in June 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company. Intrexon T1D Partners Collaboration In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a joint venture between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of $10,000 . The Company received reimbursement of research and development services provided pursuant to the ECC agreement. In November 2018, the Company completed an asset acquisition with the T1D Investors, resulting in the Company owning 100% of the membership interest of Intrexon T1D Partners including all rights under the ECC (Note 4 ). Genten Therapeutics Collaboration In September 2016, the Company entered into an ECC with Genten Therapeutics, an affiliate of Harvest and a related party. Genten Therapeutics was formed for the purpose of entering into the ECC and developing and commercializing products using the Company's technology for expression of gluten peptides, alone or in combination with immunomodulatory cytokines, to reestablish immune tolerance for patients with celiac disease. Upon execution of the ECC, the Company received a technology access fee in the form of a $1,500 cash payment and equity in Genten Therapeutics valued at $3,000 as upfront consideration. The Company received reimbursement payments for research and development services provided pursuant to the ECC. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests of Genten Therapeutics including all rights under the ECC (Note 3 ). CRS Bio Collaboration In September 2016, the Company entered into an ECC with CRS Bio, an affiliate of Harvest and a related party. CRS Bio was formed for the purpose of entering into the ECC and developing and commercializing products through targeted delivery of antibodies for treatment of chronic rhinosinusitis with and without nasal polyps, by utilizing the Company's technology to block inflammatory mediators in the nasal passage, leading to improved breathing and, importantly, patients' quality of life. Upon execution of the ECC, the Company received a technology access fee in the form of equity in CRS Bio valued at $2,100 . The Company received reimbursement payments for research and development services provided pursuant to the ECC. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests of CRS Bio including all rights under the ECC (Note 3 ). Relieve Genetics Collaboration In March 2016, the Company entered into an ECC with Relieve Genetics, an affiliate of Harvest and a related party. Relieve Genetics was formed for the purpose of entering into the ECC and developing and commercializing products using a viral vector expressing interleukin-10 for the treatment of chronic neuropathic pain resultant from cancer in humans. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Relieve Genetics valued at $4,333 as upfront consideration. The Company received reimbursement payments for research and development services provided pursuant to the ECC. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests of Relieve Genetics including all rights under the ECC (Note 3 ). Intrexon Energy Partners Collaboration In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a joint venture between the Company and certain investors and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The Company receives reimbursement payments for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March 2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company. Intrexon Energy Partners II Collaboration In December 2015, the Company entered into an ECC with Intrexon Energy Partners II, a joint venture between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon Energy Partners II received an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of 1,4-butanediol (BDO), a key chemical intermediate that is used to manufacture spandex, polyurethane, plastics, and polyester. Upon execution of the ECC, the Company received a technology access fee of $18,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in December 2015 and continues until December 2035; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated voluntarily by Intrexon Energy Partners II upon 90 days written notice to the Company. Exotech Bio Collaboration In March 2016, the Company entered into an ECC with Exotech Bio, Inc. ("Exotech Bio"), an affiliate of Harvest and a related party. Exotech Bio was formed for the purpose of entering into the ECC and developing and commercializing products using exosomes carrying a RNA payload designed to kill, suppress, or render immune-visible a cancer cell. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Exotech Bio valued at $5,000 as upfront consideration. In June 2018, the Company and Exotech Bio amended the ECC, which resulted in the expansion of the defined field of use and the Company's ownership in Exotech Bio increasing to 49% . The amendment also eliminated potential future milestone payments and royalties for which the Company was previously entitled. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Exotech Bio upon 90 days written notice to the Company. AD Skincare Collaboration In June 2016, the Company entered into an ECC with AD Skincare, Inc. ("AD Skincare"), an affiliate of Harvest and a related party. AD Skincare was formed for the purpose of entering into the ECC and developing an advanced topical delivery system to improve the efficacy of biologically active ingredients aimed at improving signs of aging human skin. Upon execution of the ECC, the Company received a technology access fee in the form of equity in AD Skincare valued at $4,333 as upfront consideration. The Company is also entitled to up to $2,000 of potential payments for substantive and non-substantive development milestones for each product developed under the ECC, as well as up to $17,000 in one-time commercial milestones. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. AD Skincare will pay the Company royalties as a percentage in the low double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. AD Skincare is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in June 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by AD Skincare upon 90 days written notice to the Company. Genopaver Collaboration In March 2013, the Company entered into an ECC with Genopaver, LLC ("Genopaver"), an affiliate of Third Security and a related party. Genopaver was formed for the purpose of entering into the ECC and developing and commercializing products in the field of the fermentative production of alkaloids through genetically modified cell-lines and substrate feeds for use as active pharmaceutical ingredients or as commercially sold intermediates in the manufacture of active pharmaceutical ingredients. Upon execution of the ECC, the Company received a technology access fee of $3,000 as upfront consideration. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Genopaver will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Genopaver is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2013 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genopaver upon 90 days written notice to the Company. Fibrocell Science Collaborations In October 2012, the Company entered into an ECC ("Fibrocell ECC 1") with Fibrocell Science, Inc. ("Fibrocell"), a publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party. Pursuant to Fibrocell ECC 1, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. Upon execution of Fibrocell ECC 1, the Company received a technology access fee of 87,835 shares of Fibrocell's common stock valued at $7,576 as upfront consideration. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during Fibrocell ECC 1 and manufacturing services for Company materials provided to Fibrocell during Fibrocell ECC 1. On a quarterly basis, Fibrocell will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each product developed from Fibrocell ECC 1, as defined in the agreement. If Fibrocell uses the Company's technology platform to improve the production of a c

Short-term Investments

Short-term Investments	12 Months Ended
	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	Short-term Investments The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value United States government debt securities $ 119,401 $ — $ (61 ) $ 119,340 Certificates of deposit 348 — — 348 Total $ 119,749 $ — $ (61 ) $ 119,688 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2017 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value United States government debt securities $ 6,000 $ — $ (2 ) $ 5,998 Certificates of deposit 275 — — 275 Total $ 6,275 $ — $ (2 ) $ 6,273 For more information on the Company's method for determining the fair value of its assets, see Note 2 – "Fair Value of Financial Instruments". As of December 31, 2018 , all of the available-for-sale investments were due within one year based on their contractual maturities. Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and were not significant as of December 31, 2018 . As of December 31, 2018 and 2017 , the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.

Investments in Preferred Stock

Investments in Preferred Stock	12 Months Ended
	Dec. 31, 2018
Investment in Preferred Stock [Abstract]
Investments In Preferred Stock	Investments in Preferred Stock Investment in ZIOPHARM Preferred Stock In June 2016, the Company received 100,000 shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM with a per share stated value of $1,200 , as consideration for amending their two previously existing ECC agreements (Note 5 ). The Company received a monthly dividend, paid in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares. In conjunction with the ZIOPHARM License Agreement in October 2018 (Note 5 ), the Company returned to ZIOPHARM all of the Preferred Shares owned or accrued by the Company as of the effective date of the agreement. The investment in ZIOPHARM preferred stock was categorized as Level 3 as there were significant unobservable inputs and the Preferred Shares were not traded on a public exchange. The fair value of the investment in ZIOPHARM preferred stock was estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model were (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. The fair value of the Company's investment in ZIOPHARM preferred stock, including additional Preferred Shares received as dividends, was $160,832 as of December 31, 2017 . During the years ended December 31, 2018 , 2017 and 2016 , the Company received and accrued an additional 11,415 , 13,460 , and 6,184 Preferred Shares, respectively, and recognized $14,793 , $16,717 , and $7,421 of dividend income in the accompanying consolidated statements of operations, respectively. Investment in Fibrocell Preferred Stock In March 2017, Fibrocell sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares") convertible into shares of Fibrocell common stock and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $1,161 in exchange for 1,161 Convertible Preferred Shares and warrants to acquire 99,769 shares of Fibrocell common stock, reflective of the 1-for-5 reverse stock split of Fibrocell's common stock effective May 25, 2018. The Convertible Preferred Shares are convertible at any time at the election of the Company and accrue dividends at 4% per annum, compounded quarterly, increasing the stated value of the shares. The investment in Fibrocell preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Convertible Preferred Shares are not traded on a public exchange. The fair value of the investment in Fibrocell preferred stock is estimated using a conversion plus dividend approach utilizing the trading value of the underlying common stock and an estimated premium for the preferred stock dividend and other preferences. Market price volatility of Fibrocell's common stock and a significant change in the estimated preferred stock premium could result in a significant impact to the fair value of the investment in Fibrocell preferred stock. As of December 31, 2018 and 2017 , the fair value of the Company's investment in Fibrocell preferred stock totaled $191 and $393 , respectively. See Note 17 for additional discussion of the warrants. Investment in Oragenics Preferred Stock In November 2017, concurrent with Oragenics closing a preferred stock private placement, the Company exchanged a promissory note, including accrued interest, purchased from Oragenics in May 2017 and receivables due from Oragenics totaling $3,385 for Oragenics Series C preferred stock ("Series C Preferred Stock"). The Series C Preferred Stock is non-voting and non-convertible and is redeemable in whole or part at any time by Oragenics in cash. The Series C Preferred Stock accrues an annual 12% dividend payable in additional Series C Preferred Stock through May 10, 2019, and after such date, the annual dividend increases to 20% . Additionally, the Company and Oragenics amended certain future payment terms under its ECCs (Note 5 ). As of December 31, 2018 and 2017 , based on the most recent financial information available on Oragenics, the Company concluded that there was no value to its investment in Oragenics preferred stock. Changes in the Fair Value of Investments in Preferred Stock The following table summarizes the changes in the Level 3 investments in preferred stock during the years ended December 31, 2018 and 2017 . 2018 2017 Beginning balance $ 161,225 $ 129,545 Purchase of preferred stock — 766 Conversion of receivables to preferred stock — 3,385 Dividend income from investments in preferred stock 14,841 16,756 Net unrealized appreciation (depreciation) in the fair value of the investments in preferred stock (17,499 ) 10,773 Return of preferred stock (158,376 ) — Ending balance $ 191 $ 161,225

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amount of cash and cash equivalents, restricted cash, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments. Assets The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2018 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, Assets United States government debt securities $ — $ 119,340 $ — $ 119,340 Equity securities 1,626 556 — 2,182 Preferred stock — — 191 191 Other — 468 — 468 Total $ 1,626 $ 120,364 $ 191 $ 122,181 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2017 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, Assets United States government debt securities $ — $ 5,998 $ — $ 5,998 Equity securities 10,537 4,563 — 15,100 Preferred stock — — 161,225 161,225 Other — 850 — 850 Total $ 10,537 $ 11,411 $ 161,225 $ 183,173 The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability. The methods used to estimate the fair value of the Level 3 assets are discussed in Note 7 . There were no transfers between levels of the fair value hierarchy during the year ended December 31, 2018 . Liabilities The carrying values of the Company's long-term debt, excluding the Convertible Notes as discussed below, approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The calculated fair value of the Convertible Notes (Note 12 ) is approximately $141,000 as of December 31, 2018 and is based on the most recent third party trade of the instrument as of the balance sheet date. The fair value of the Convertible Notes are classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third party trades of the instrument are considered observable inputs. The Convertible Notes are reflected at amortized cost on the accompanying consolidated balance sheet, which was $148,101 as of December 31, 2018 . The Company's contingent consideration liabilities (Notes 3 and 4 ) are measured on a recurring basis and were $585 as of December 31, 2018 and 2017 . These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. The changes in the fair value of the Level 3 liabilities during the years ended December 31, 2018 and 2017 were as follows: 2018 2017 Beginning balance $ 585 $ 2,081 Acquisition date fair value of contingent consideration liability — 585 Change in fair value of contingent consideration recognized in selling, general and administrative expenses — (2,081 ) Ending balance $ 585 $ 585

Inventory

Inventory	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: December 31, 2018 2017 Supplies, embryos and other production materials $ 4,729 $ 2,673 Work in process 4,391 4,767 Livestock 10,167 11,040 Feed 2,160 2,013 Total inventory $ 21,447 $ 20,493

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment consist of the following: December 31, 2018 2017 Land and land improvements $ 12,490 $ 11,767 Buildings and building improvements 20,371 18,183 Furniture and fixtures 1,891 2,515 Equipment 74,555 65,863 Leasehold improvements 28,289 25,277 Breeding stock 4,582 3,832 Computer hardware and software 11,697 10,128 Trees 11,910 6,642 Construction and other assets in progress 18,880 14,113 184,665 158,320 Less: Accumulated depreciation and amortization (55,791 ) (45,646 ) Property, plant and equipment, net $ 128,874 $ 112,674 During the year ended December 31, 2018 , the Company recorded a $5,057 loss on disposal of certain leasehold improvements, equipment, and other fixed assets in conjunction with the closing of one of its research and development facilities in Brazil. Additionally, included in the table above is $14,219 of land, buildings, and equipment related to a 2017 asset acquisition of a land-based aquaculture facility to be used in the production of AquAdvantage salmon in Indiana. Depreciation expense was $14,328 , $11,951 and $9,387 for the years ended December 31, 2018 , 2017 and 2016 , respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017 , are as follows: 2018 2017 Beginning balance $ 153,289 $ 157,175 Acquisitions — 4,850 Impairment — (13,823 ) Foreign currency translation adjustments (3,704 ) 5,087 Ending balance $ 149,585 $ 153,289 For the year ended December 31, 2017 , the Company recorded a goodwill impairment charge since, based on the price per share received by AquaBounty in its recent underwritten public offering (Note 14 ), it was more-likely-than-not that the fair value of the AquaBounty reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the AquaBounty reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $13,001 goodwill impairment charge for the excess carrying value. The Company did not recognize any goodwill impairment charges during the years ended December 31, 2018 or 2016 . The Company had $13,823 of accumulated impairment losses as of December 31, 2018 . Intangible assets consist of the following as of December 31, 2018 : Weighted Average Useful Life (Years) Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how 15.5 $ 152,482 $ (35,133 ) $ 117,349 Customer relationships 6.5 10,700 (7,565 ) 3,135 Trademarks 9.3 6,800 (3,341 ) 3,459 In-process research and development 5,348 — 5,348 Total $ 175,330 $ (46,039 ) $ 129,291 Intangible assets consist of the following as of December 31, 2017 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 263,615 $ (44,954 ) $ 218,661 Customer relationships 10,700 (6,383 ) 4,317 Trademarks 6,800 (2,567 ) 4,233 In-process research and development 5,666 — 5,666 Total $ 286,781 $ (53,904 ) $ 232,877 The balance of in-process research and development includes certain in-process research and development technology acquired in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have been obtained for the in-process programs. In the fourth quarter of 2018, the Company recorded an impairment charge of $60,504 due to a change in the Company's business strategy for commercializing the Oxitec developed technology targeting the Aedes Aegypti mosquito, resulting in a lack of projected future cash flows to support the carrying value of the asset. In 2017, the Company recorded an impairment charge of $2,950 as part of its annual impairment assessment of indefinite-lived intangible assets due to the lack of projected future cash flows to support certain in-process research and development. Additionally, in the fourth quarter of 2018, the Company recorded a $16,027 loss related to the abandonment of certain developed technologies that the Company ceased using in the fourth quarter of 2018. The Company does not expect to use these technologies as a defensive asset or market them for sale in the future. Because these technologies were used in combination with other technologies, the identifiable cash flows did not result in an impairment; however, because the Company made a decision to abandon the assets, it recorded the charge to research and development expense. Amortization expense was $18,784 , $19,194 and $15,185 for the years ended December 31, 2018 , 2017 and 2016 , respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows: 2019 $ 11,966 2020 11,863 2021 11,675 2022 10,676 2023 9,798 Thereafter 67,965 Total $ 123,943

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Lines of Credit and Long-Term Debt	Lines of Credit and Long-Term Debt Lines of Credit Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha that matures on May 1, 2019. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% , and the actual rate was 5.30% as of December 31, 2018 . As of December 31, 2018 , there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of December 31, 2018 . Exemplar has a $700 revolving line of credit with American State Bank that matures on October 30, 2019. The line of credit bears interest at 5.75% per annum. As of December 31, 2018 , there was an outstanding balance of $466 . Long-Term Debt Long-term debt consists of the following: December 31, 2018 2017 Convertible debt $ 203,391 $ — Notes payable 4,551 5,010 Royalty-based financing 2,085 2,132 Other 1,767 895 Long-term debt 211,794 8,037 Less current portion 559 502 Long-term debt, less current portion $ 211,235 $ 7,535 Convertible Debt Intrexon Convertible Notes In July 2018, Intrexon completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Intrexon and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Intrexon received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042 . The Convertible Notes are senior unsecured obligations of Intrexon and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023, unless earlier repurchased or converted. The Convertible Notes are convertible into cash, shares of Intrexon's common stock or a combination of cash and shares, at Intrexon's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Intrexon common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Intrexon will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances: • During any calendar quarter commencing after the calendar quarter ending on September 30, 2018, if the last reported sales price of Intrexon's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Intrexon's common stock and the conversion rate for the Convertible Notes on each such trading day; or • Upon the occurrence of specified corporate events as defined in the Indenture. None of the above events allowing for conversion prior to April 1, 2023 occurred during the year ended December 31, 2018 . On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Intrexon may not redeem the Notes prior to the maturity date. If Intrexon undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Intrexon to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Intrexon shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Intrexon's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture. The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, at $143,723 and additional paid-in capital, the equity component, at $50,235 . Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on current year domestic operating losses in the same amount (Note 13 ). As of December 31, 2018 , the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $148,101 . The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02% . As of December 31, 2018 , the unamortized long-term debt discount and debt issuance costs totaled $51,899 . Total interest expense related to the Convertible Notes was $7,840 for the year ended December 31, 2018 , which consists of $3,462 cash interest expense paid in December and $4,378 of noncash interest expense. ActoBio Convertible Notes In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest (Note 3 ). The ActoBio Notes have a maturity date of September 6, 2020, accrue interest at 3.0% compounded annually, are convertible into shares of ActoBio common stock at any time by the holder, and are automatically convertible in shares of ActoBio common stock upon the closing of certain financing events as defined in the ActoBio Notes. If the ActoBio Notes have not been converted to ActoBio common stock by the maturity date, ActoBio can pay the principal and accrued interest in cash or with shares of Intrexon common stock at its election. There are no embedded features that are required to be separated from the debt host and accounted for separately, so the ActoBio Notes were recorded at $30,000 . Interest expense for the year ended December 31, 2018 was $290 . As of December 31, 2018 , the carrying value of the ActoBio Notes, including accrued interest, was $30,290 . Intrexon and Precigen Convertible Note In December 2018, in conjunction with the Merck Purchase Agreement (Note 5 ), Intrexon and Precigen jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note has a maturity date of June 28, 2021 and will be converted to Intrexon common stock on the first trading day following maturity if not otherwise converted prior to that date. Prior to maturity, Ares Trading may convert the Merck Note, at their election, into (i) Intrexon common stock at any time, (ii) Intrexon common stock upon the Company's closing of qualified financing as defined in the agreement, (iii) Precigen equity upon Precigen closing a qualified financing as defined in the agreement, and (iv) Precigen common stock upon the closing of a qualified initial public offering ("IPO") of Precigen common stock. In the event of a conversion upon a qualified IPO, the conversion price will be 90% of the IPO price. In the event Ares Trading elects to convert the Merck Note into Precigen equity, the Merck Note accrues interest at a rate of 5% per year ("PIK interest") and will be converted with the outstanding principal. The Company determined that the potential PIK interest and IPO conversion discount represented embedded derivatives requiring bifurcation from the debt host but had no significant value as of December 31, 2018 . Notes Payable Trans Ova has a note payable to American State Bank that matures in April 2033 and has an outstanding principal balance of $4,482 as of December 31, 2018 . Trans Ova pays monthly installments of $39 , which includes interest at 3.95% . The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets. Royalty-based Financing AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency, a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was $2,107 , which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. As of the date of the acquisition by Intrexon in March 2013, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107 . The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Subsequent to the acquisition date, AquaBounty claimed the remaining balance available under the grant, resulting in total long term debt of $2,085 as of December 31, 2018 . Future Maturities Future maturities of long-term debt are as follows: 2019 $ 559 2020 30,843 2021 25,405 2022 420 2023 201,442 Thereafter 2,939 Total $ 261,608 The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of loss before income taxes are presented below: Year Ended December 31, 2018 2017 2016 Domestic $ (443,337 ) $ (71,343 ) $ (157,067 ) Foreign (92,897 ) (58,357 ) (37,084 ) Loss before income taxes $ (536,234 ) $ (129,700 ) $ (194,151 ) The components of income tax expense (benefit) are presented below: Year Ended December 31, 2018 2017 2016 United States federal income taxes: Current $ (31 ) $ 27 $ (17 ) Deferred (11,855 ) (523 ) 1,396 Foreign income taxes: Current (332 ) (379 ) (393 ) Deferred (5,068 ) (2,269 ) (5,177 ) State income taxes: Current 113 — — Deferred (4,355 ) 264 314 Income tax benefit $ (21,528 ) $ (2,880 ) $ (3,877 ) Income tax benefit for the years ended December 31, 2018 , 2017 and 2016 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% for 2018 , and 34% for years prior to 2018, to loss before income taxes as a result of the following: 2018 2017 2016 Computed statutory income tax benefit $ (112,609 ) $ (44,098 ) $ (66,011 ) State and provincial income tax benefit, net of federal income taxes (24,724 ) (3,294 ) (7,905 ) Nondeductible stock based compensation 1,834 4,147 3,321 Nondeductible officer compensation 294 476 — Gain on dividend distribution of AquaBounty common stock — 3,965 — Impairment of goodwill — 4,700 — Research and development tax incentives (1,088 ) (1,166 ) (6,350 ) Acquisition and internal restructuring transaction costs 52 354 571 Provisional impact of the Tax Act — 85,288 — Enacted changes in foreign tax rates and foreign tax reforms — 2,138 — Reacquired in-process research and development 2,696 — — Change in deferred state tax rate 8,666 — — United States-foreign rate differential 3,017 5,410 3,463 Other, net (486 ) (64 ) 1,485 (122,348 ) 57,856 (71,426 ) Change in valuation allowance for deferred tax assets 100,820 (60,736 ) 67,549 Total income tax benefit $ (21,528 ) $ (2,880 ) $ (3,877 ) The tax effects of temporary differences that comprise the deferred tax assets and liabilities as of December 31, 2018 and 2017 , are as follows: 2018 2017 Deferred tax assets Allowance for doubtful accounts $ 1,490 $ 1,300 Inventory 614 489 Equity securities and investments in affiliates 30,241 17,510 Intangible assets 71,205 — Accrued liabilities 4,412 3,131 Stock-based compensation 29,297 26,936 Deferred revenue 16,297 61,785 Research and development tax credits 11,597 11,385 Net operating and capital loss carryforwards 148,411 111,453 Total deferred tax assets 313,564 233,989 Less: Valuation allowance 308,113 215,582 Net deferred tax assets 5,451 18,407 Deferred tax liabilities Property, plant and equipment 528 237 Intangible assets — 33,790 Long-term debt 12,136 — Total deferred tax liabilities 12,664 34,027 Net deferred tax liabilities $ (7,213 ) $ (15,620 ) Activity within the valuation allowance for deferred tax assets during the years ended December 31, 2018 , 2017 and 2016 was as follows: 2018 2017 2016 Valuation allowance at beginning of year $ 215,582 $ 256,165 $ 190,174 Increase (decrease) in valuation allowance as a result of Mergers and acquisitions, net 418 — (1,416 ) Current year operations 122,853 26,619 67,549 Adoption of ASC 606 (7,477 ) — — Adoption of ASU 2016-09 — 17,843 — Provisional impact of the Tax Act — (87,473 ) — Equity component of long-term debt (13,367 ) — — Change in deferred state tax rate (8,666 ) — — Changes in foreign tax rates and foreign tax reforms — 1,327 — Foreign currency translation adjustment (1,230 ) 1,101 (142 ) Valuation allowance at end of year $ 308,113 $ 215,582 $ 256,165 In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein. The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December 31, 2018 , all such limited losses applicable to Intrexon, other than losses inherited via acquisition, have been fully utilized. As of December 31, 2018 , approximately $41,909 of the Company's domestic net operating losses were inherited via acquisition, including $13,376 acquired via the acquisition of GenVec, and are limited based on the value of the target at the time of the transaction. As of December 31, 2018 , the Company has loss carryforwards for United States federal income tax purposes of approximately $369,102 available to offset future taxable income, including $116,600 generated after 2017, and federal and state research and development tax credits of $7,881 , prior to consideration of annual limitations that may be imposed under Section 382. Carryforwards generated prior to 2018 will begin to expire in 2022 . The Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $159,811 , most of which do not expire. The Company does not record deferred taxes on the undistributed earnings of its direct foreign subsidiaries because it does not expect the temporary differences related to those unremitted earnings to reverse in the foreseeable future. As of December 31, 2018 , the Company's direct foreign subsidiaries had accumulated deficits of approximately $150,409 . Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to United States income and foreign withholding taxes. The Company does not file a consolidated income tax return with AquaBounty. As of December 31, 2018 , AquaBounty has loss carryforwards for federal and foreign income tax purposes of approximately $37,807 , including $9,370 generated after 2017, and $14,007 , respectively, and foreign tax credits of approximately $2,628 available to offset future taxable income, prior to consideration of annual limitations that may be imposed under Section 382 or analogous foreign provisions. Carryforwards generated prior to 2018 began to expire in 2018 . As a result of the Company's ownership in AquaBounty passing 50% in 2013, an annual Section 382 of approximately $900 per year will apply to domestic losses and credits carried forward by AquaBounty from prior years, which are also subject to prior Section 382 limitations. In the year ended December 31, 2017, the Company recorded a net provisional income tax benefit of $2,185 upon enactment of the Tax Act, which is comprised of several items. Amounts related to the remeasurement of most of the Company's domestic deferred tax assets as a result of the United States corporate rate change to 21% as part of the Tax Act are $87,473 , which was fully offset by a reduction in the Company's valuation allowance. The Company's net United States deferred tax liability that is not offset by a valuation allowance was similarly written down, and the Company recorded a provisional deferred tax benefit of $1,730 . The Company also recorded a provisional current tax benefit of $455 related to the expected refundability of accumulated corporate alternative minimum tax credits. The Company provisionally estimated its transition tax exposure to be zero , as any accumulated earnings in foreign subsidiaries are offset by accumulated deficits in other foreign subsidiaries. The Company completed its accounting for the Tax Act in the fourth quarter of 2018, and there were no significant adjustments to the previously recorded provisional amounts. Additionally, in December 2017, Belgium enacted significant tax reform measures, the most significant of which to the Company is the limitation on the utilization of accumulated losses in years after 2017. After that date, loss carryforwards can only be used to offset 70% of taxable income that exceeds a certain threshold. As a result, the Company recorded adjustments to its net deferred tax assets and valuation allowances. These adjustments resulted in a net deferred tax liability of $2,307 , which was recorded as a component of deferred tax expense for the year ended December 31, 2017. The Company and its subsidiaries do not have material unrecognized tax benefits as of December 31, 2018 . The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating losses and research and development tax credits.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Issuances of Intrexon Common Stock In January 2018, Intrexon closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374 , after deducting underwriting discounts of $3,688 and offering expenses of $188 , all of which were capitalized. In December 2017, the Company entered into a securities purchase agreement with an affiliate of Third Security for the private placement of 1,207,980 shares of the Company's common stock for gross proceeds of $13,686 . Share Lending Agreement Concurrently with the offering of the Convertible Notes (Note 12 ), Intrexon entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Intrexon loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Intrexon within five business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Intrexon did not receive any proceeds from the sale of the Borrowed Shares to the public. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering. The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Intrexon shareholders unless the Share Borrower defaults on the Share Lending Agreement. Issuances of AquaBounty Common Stock In January 2018, AquaBounty completed an underwritten public offering that resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Intrexon purchased $5,000 of additional AquaBounty common stock. In October 2018, certain investors exercised warrants acquired from the January 2018 offering, resulting in additional net proceeds of $4,316 , including $3,077 from Intrexon. In January 2017, in conjunction with the listing by AquaBounty of their common stock on the NASDAQ Stock Market, Intrexon purchased $25,000 of additional AquaBounty common stock and subsequently distributed shares of AquaBounty common stock as a dividend to Intrexon shareholders. Dividends to Shareholders In January 2017, the Company distributed to its shareholders 1,776,557 shares of AquaBounty common stock valued at $22,385 . The distribution constituted a dividend to shareholders of record as of January 9, 2017. In connection with the distribution and pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of January 9, 2017 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number outstanding options. This adjustment resulted in 46,766 additional outstanding options at a weighted average exercise price of $31.11 . Components of Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows: December 31, 2018 2017 Unrealized loss on investments $ (61 ) $ (2 ) Loss on foreign currency translation adjustments (28,551 ) (15,552 ) Total accumulated other comprehensive loss $ (28,612 ) $ (15,554 )

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments The Company records the fair value of stock options and RSUs issued to employees and nonemployees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below: Year Ended December 31, 2018 2017 2016 Cost of products $ 78 $ 116 $ 81 Cost of services 237 322 274 Research and development 9,676 9,336 9,251 Selling, general and administrative 26,305 31,802 32,596 Total $ 36,296 $ 41,576 $ 42,202 Intrexon Stock Option Plans In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of December 31, 2018 , there were 410,909 stock options outstanding under the 2008 Plan. Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share-based awards, including stock options, and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of December 31, 2018 , there were 20,000,000 shares authorized for issuance under the 2013 Plan, of which 10,682,154 stock options and 970,341 RSUs were outstanding and 5,086,700 shares were available for grant. Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain United States Treasury regulations. Virtually all stock options have ten -year terms and vest four years from the date of grant. Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2015 11,043,528 $ 32.66 8.49 Granted 4,644,860 29.39 Exercised (1,210,840 ) (15.83 ) Forfeited (2,760,809 ) (40.34 ) Expired (76,356 ) (37.81 ) Balances at December 31, 2016 11,640,383 31.25 8.21 Granted 3,920,950 21.47 Adjustment due to dividend (Note 14) 46,766 31.11 Exercised (149,429 ) (6.37 ) Forfeited (3,797,105 ) (28.37 ) Expired (278,818 ) (33.18 ) Balances at December 31, 2017 11,382,747 28.99 7.32 Granted 1,470,339 14.26 Exercised (45,159 ) (6.59 ) Forfeited (929,596 ) (21.48 ) Expired (785,268 ) (26.25 ) Balances at December 31, 2018 11,093,063 27.95 6.81 Exercisable at December 31, 2018 7,002,519 30.37 5.97 Total unrecognized compensation costs related to unvested awards as of December 31, 2018 were $37,353 , and are expected to be recognized over a weighted-average period of approximately two years . The weighted average grant date fair value of options granted during 2018 , 2017 and 2016 was $7.94 , $12.19 and $16.28 , respectively. The aggregate intrinsic value of options exercised during 2018 , 2017 and 2016 was $356 , $2,429 and $22,704 , respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Intrexon's common stock for those shares where the exercise price was lower than the fair value of Intrexon's common stock on the date of exercise. The following table summarizes additional information about stock options outstanding as of December 31, 2018 : Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 3.17 — $ 19.52 1,973,818 $ 13.70 7.54 $ 169 833,007 $ 12.80 4.85 $ 169 $ 19.85 — $ 20.94 1,914,763 20.93 7.99 — 500,263 20.92 7.67 — $ 21.00 — $ 27.08 2,057,126 23.29 7.26 — 1,248,370 23.01 6.69 — $ 27.10 — $ 29.56 2,666,109 29.19 5.28 — 2,593,151 29.20 5.23 — $ 29.58 — $ 65.08 2,481,247 47.24 6.59 — 1,827,728 47.65 6.54 — 11,093,063 $ 27.95 6.81 $ 169 7,002,519 $ 30.37 5.97 $ 169 The following table summarizes additional information about stock options outstanding as of December 31, 2017 : Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 2.64 — $ 9.30 453,371 $ 7.06 3.94 $ 2,020 453,371 $ 7.06 3.94 $ 2,020 $ 12.50 — $ 21.38 3,158,121 20.58 8.74 — 456,942 19.52 7.13 — $ 21.43 — $ 28.81 3,399,721 25.55 6.91 — 1,804,401 25.86 5.69 — $ 28.88 — $ 40.99 2,751,716 32.07 6.70 — 1,732,250 31.51 6.32 — $ 41.41 — $ 65.08 1,619,818 53.52 7.42 — 859,733 53.07 7.38 — 11,382,747 $ 28.99 7.32 $ 2,020 5,306,697 $ 29.96 6.14 $ 2,020 RSU activity was a follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2017 — $ — 0.00 Granted 1,069,126 13.84 Vested (25,000 ) (15.82 ) Forfeited (73,785 ) (13.47 ) Balances at December 31, 2018 970,341 13.82 1.43 Total unrecognized compensation costs related to unvested RSU awards as of December 31, 2018 were $9,641 , and are expected to be recognized over a weighted-average period of approximately three years . Intrexon currently uses authorized and unissued shares to satisfy share award exercises. The Company's Chief Executive Officer ("CEO") receives a base salary of $200 per month payable in fully vested shares of Intrexon common stock with such shares subject to a three -year lock-up on resale. The monthly number of shares of common stock is calculated based on the closing price on the last trading day of each month and the shares are issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement expires March 31, 2019 and is subject to renewal annually by the compensation committee of the board of directors of the Company. The fair value of the shares issued as compensation for services is included in selling, general, and administrative expenses in the Company's consolidated statements of operations and totaled $1,956 , $1,908 , and $1,861 for the years ended December 31, 2018 , 2017 and 2016 , respectively. AquaBounty Stock Option Plans In March 2016, AquaBounty's board of directors adopted the AquaBounty 2016 Equity Incentive Plan ("AquaBounty 2016 Plan") to replace the AquaBounty 2006 Equity Incentive Plan ("AquaBounty 2006 Plan"). The AquaBounty 2016 Plan provides for the issuance of incentive stock options, non-qualified stock options and awards of restricted and direct stock purchases to directors, officers, employees, and consultants of AquaBounty. The AquaBounty 2016 Plan was approved by AquaBounty's shareholders at its annual meeting in April 2016. Upon the effectiveness of the AquaBounty 2016 Plan, no new awards may be granted under the AquaBounty 2006 Plan. As of December 31, 2018 , there were 339,964 options outstanding under both AquaBounty plans, of which 303,986 were exercisable, at a weighted average exercise price of $7.09 per share. As of December 31, 2017 , there were 227,203 options outstanding under these plans, of which 192,748 were exercisable, at a weighted average exercise price of $9.39 per share.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases The Company leases certain facilities and equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. As of December 31, 2018 , future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows: 2019 $ 9,182 2020 9,910 2021 9,127 2022 8,305 2023 7,229 Thereafter 34,157 Total $ 77,910 Rent expense, including other facility expenses, was $13,076 , $11,064 and $8,593 in 2018 , 2017 and 2016 , respectively. Purchase Commitments As of December 31, 2018 , the Company had outstanding contractual purchase commitments of $20,055 , which primarily relate to amounts that will be paid in 2019 and 2020 upon delivery of commercial non-browning apple trees. Contingencies In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's activities breached a 2004 licensing agreement and infringed on patents that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. In Colorado District Court, the matter proceeded to a jury trial in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial order, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with a compulsory license to XY's technology, subject to an ongoing royalty obligation. Both parties appealed the district court's order, which appeal was decided in May 2018 by the Court of Appeals for the Federal Circuit. The Court denied Trans Ova's appeal of its claims for antitrust, breach of contract and patent invalidity (except as to one patent, for which the Court affirmed invalidity in a separate, same-day ruling in a third-party case). The Court considered the issue of willfulness to be moot since the district court did not award damages for the willfulness finding. Finally, the Court remanded the district court's calculation of the ongoing royalty and instructed the district court to re-calculate the ongoing royalty in light of post-verdict economic factors. Since the inception of the 2004 agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the April 2016 court order, and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the 2004 agreement through the court's April 2016 order, aggregate royalty and license payments were $3,170 , of which $2,759 had not yet been deposited by XY. In the year ended December 31, 2016, the Company recorded expense of $4,228 , which is included in selling, general and administrative expenses on the accompanying consolidated statement of operations, representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the court's treasury, to be held until the appeals process is complete and final judgment amounts are determined. As of December 31, 2018 , this amount is included in restricted cash on the accompanying consolidated balance sheet. In December 2016, Trans Ova elected to void the outstanding checks discussed above, and these amounts have been reclassified to other accrued liabilities on the accompanying consolidated balance sheets as of December 31, 2018 and 2017 . In December 2016, XY filed a complaint for patent infringement and trade secret misappropriation against Trans Ova in the District Court of Waco, Texas. Since the claims in this 2016 complaint directly relate to the 2012 licensing dispute and patent issues, Trans Ova filed and was granted a motion for change of venue to Colorado District Court. Trans Ova also filed a motion to dismiss, from which the Court dismissed ten of the twelve counts of the complaint. Presently, two counts for patent infringement remain pending. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation. The Company may become subject to other claims, assessments and governmental investigations from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2018 and 2017 , the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's CEO and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. In November 2015, the independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. As consideration for providing these services, Third Security is entitled to a fee of $800 per month to be paid in the form of fully-vested shares of the Company's common stock. The number of shares of common stock is calculated based on the closing price of the Company's common stock on the 15th day of each month. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan (Note 15 ). The Services Agreement had a term of one year , can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's board of directors. The independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2019. For the years ended December 31, 2018 , 2017 and 2016 , the Company issued 696,033 shares, 500,650 shares, and 337,163 shares, respectively, with values of $8,324 , $8,704 , and $8,571 , respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement was $47 , $409 , and $309 for the years ended December 31, 2018 , 2017 and 2016 , respectively. See also Note 15 regarding compensation arrangements between the Company and its CEO. In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Equity Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Equity Facility, the Company could, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $100,000 of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). In conjunction with the Company's July 2018 registered underwritten public offering of Convertible Notes (Note 12 ), the Preferred Stock Equity Facility was terminated. No shares of Series A Preferred Stock had been issued under the Preferred Stock Equity Facility. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $89 , $43 , and $43 for the years ended December 31, 2018 , 2017 and 2016 , respectively. Transactions with ECC Parties In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and that also are party to a collaboration with the Company are considered to be related parties. During 2018, the Company mutually terminated each of its ECC agreements with Histogenics Corporation ("Histogenics"), OvaScience, and Synthetic Biologics, Inc. ("Synthetic Biologics"). Upon termination of these ECCs, the Company recognized the remaining deferred revenue totaling $11,877 . In December 2017, the Company purchased certain property and equipment comprising the pilot plant production facility for its energy programs for $2,812 from Intrexon Energy Partners. The Company intends to use the pilot plant to support the collaborations with Intrexon Energy Partners and Intrexon Energy Partners II and its own research programs. The Company holds a promissory note convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock. As of December 31, 2018 and 2017 , the value of the convertible note and warrants totaled $120 and $575 , respectively, and is included in other assets on the accompanying consolidated balance sheets. In June 2016, the Company purchased 226,142 shares of Oragenics common stock at $5.20 per share. In December 2016, the Company sold all of its investment in AmpliPhi Biosciences Corporation common stock, resulting in a realized loss of $4,098 , which is included in unrealized and realized depreciation in fair value of equity securities on the consolidated statement of operations for the year ended December 31, 2016. Other Related Parties In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development start-up opportunities that the Company offered to Harvest with exclusive rights of first-look and first negotiation. Based on this agreement, Harvest established six new collaboration entities, each of which entered into an ECC with the Company in a designated field. The terms of such ECCs were negotiated between the Company and Harvest. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company received a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $1,839 and $2,483 for the years ended December 31, 2017 and 2016 , respectively. In September 2017, the commitment period for Harvest was terminated and, as a result, the agreement with Harvest terminated. The termination of the agreement had no effect on the existing collaborations with Harvest-controlled entities. See Note 3 for further discussion of the asset acquisition of certain Harvest entities.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share The following table presents the computation of basic and diluted net loss per share: 2018 2017 2016 Historical net loss per share: Numerator: Net loss attributable to Intrexon $ (509,336 ) $ (117,018 ) $ (186,612 ) Denominator: Weighted average shares outstanding, basic and diluted 129,521,731 119,998,826 117,983,836 Net loss attributable to Intrexon per share, basic and diluted $ (3.93 ) $ (0.98 ) $ (1.58 ) The following potentially dilutive securities as of December 31, 2018 , 2017 , and 2016 , have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive: December 31, 2018 2017 2016 Convertible debt 18,955,668 — — Options 11,093,063 11,382,747 11,640,383 Restricted stock units 970,341 — — Warrants 133,264 133,264 — Total 31,152,336 11,516,011 11,640,383

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	Quarterly Financial Information (Unaudited) The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. Three Months Ended March 31, June 30, September 30, December 31, 2018 (1) Total revenues $ 39,666 $ 45,275 $ 32,448 $ 43,185 Operating loss (52,522 ) (49,735 ) (66,471 ) (336,882 ) Net loss (47,409 ) (66,829 ) (58,746 ) (341,722 ) Net loss attributable to Intrexon (46,165 ) (65,382 ) (57,324 ) (340,465 ) Net loss attributable to Intrexon per share, basic and diluted $ (0.36 ) $ (0.51 ) $ (0.44 ) $ (2.59 ) (1) During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5 ). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11 ). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17 ). Three Months Ended March 31, June 30, September 30, December 31, 2017 (1) Total revenues $ 53,504 $ 54,433 $ 46,016 $ 77,028 Operating loss (31,381 ) (35,270 ) (44,747 ) (26,492 ) Net loss (32,377 ) (19,662 ) (40,836 ) (33,945 ) Net loss attributable to Intrexon (31,399 ) (18,664 ) (39,689 ) (27,266 ) Net loss attributable to Intrexon per share, basic and diluted $ (0.26 ) $ (0.16 ) $ (0.33 ) $ (0.23 ) (1) During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5 ). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11 ).

Defined Contribution Plans

Defined Contribution Plans	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Defined Contribution Plans	Defined Contribution Plans The Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans were $2,493 , $2,367 and $1,857 in 2018 , 2017 and 2016 , respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Revenue Recognition	Revenue Recognition (For the Year Ended December 31, 2018) Effective January 1, 2018, the Company applies Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations. Collaboration and licensing revenues The Company generates collaboration and licensing revenues through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement; (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities; and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days . The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and in certain cases manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement. At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606. The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate. As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company. From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue. Product and service revenues The Company generates product and service revenues primarily through sales of products and services that are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days . Revenue Recognition (For the Years Ended December 31, 2017 and 2016) Collaboration and licensing revenues The Company generates collaboration and licensing revenue through collaboration and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement. Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations, which is reevaluated each reporting period. The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria: (1) The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone; (2) The consideration relates solely to past performance; and (3) The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments. Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned. From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue. Product and service revenues The Company generates product and service revenues primarily through sales of products and services that are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.
Research and Development	Research and Development The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in research and development. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.
Cash and Cash Equivalents	Cash and Cash Equivalents All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer.
Restricted Cash	Restricted Cash Restricted cash represents funds deposited with the United States Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 16 ).
Short-term and Long-term Investments	Short-term and Long-term Investments As of December 31, 2018 , short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard & Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.
Equity Securities	Equity Securities The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statements of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. Equity securities that the Company does not intend to sell within one year are classified as noncurrent in the consolidated balance sheet. The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
Investment in Preferred Stock	Investments in Preferred Stock The Company holds preferred stock in certain of its collaborators, most of which may be converted to common stock as described in Note 7 . The Company elected the fair value option to account for its investments in preferred stock whereby the value of preferred stock is adjusted to fair value as of each reporting date and unrealized gains and losses are reported in the consolidated statements of operations. These investments are subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of certain of the preferred stock into common stock, the volatility of each collaborator's common stock, and changes in general economic and financial conditions of the collaborators. The investments are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell the investments nor expect the investments that are convertible into common stock to be converted within one year. The Company is entitled to monthly dividends and records dividend income as described in Note 7 .
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1: Quoted prices in active markets for identical assets and liabilities; Level 2: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.
Concentrations of Risk	Concentrations of Risk Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2018 , gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.
Equity Method Investments	Equity Method Investments The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note 17 ) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Note 3 .
Variable Interest Entities	Variable Interest Entities The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.
Trade Receivables	Trade Receivables Trade receivables consist of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.
Inventory	Inventory The Company's inventory primarily includes adult female cows that are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows: Years Land improvements 4–20 Buildings and building improvements 3–25 Furniture and fixtures 1–10 Equipment 1–10 Breeding stock 1–4 Computer hardware and software 1–7 Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to twenty years
Goodwill	Goodwill Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the goodwill impairment test is not required. If the goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary. The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.
Intangible Assets	Intangible Assets Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development technologies acquired in mergers or acquisitions and were recorded at fair value at the dates of the respective acquisitions. The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from three to twenty-one years for the patents, developed technologies and know-how; customer relationships; and trademarks.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.
Convertible Notes	Convertible Notes The Company allocated the proceeds received in July 2018 from the issuance of Intrexon's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt is the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represents the value of the conversion option and is calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs related to the Convertible Notes are also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital are recorded as reduction of the original value assigned to the conversion option.
Foreign Currency Translation	Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
Share-Based Payments	Share-Based Payments Intrexon uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Since Intrexon does not have sufficient history to estimate the expected volatility of its common stock price, expected volatility is based on a blended approach that utilizes the volatility of Intrexon's common stock and the volatility of peer public entities that are similar in size and industry. Intrexon estimates the expected term of all options based on previous history of exercises. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Intrexon does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("NASDAQ"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2018 , 2017 and 2016 are set forth in the table below: 2018 2017 2016 Valuation assumptions Expected dividend yield 0% 0% 0% Expected volatility 55%—59% 57%—60% 59%—60% Expected term (years) 6.25 6.25 6.25 Risk-free interest rate 2.33%—3.06% 1.89%—2.27% 1.23%—2.17% Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the NASDAQ on the date of grant.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information	Segment Information While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services primarily associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in one segment.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company adopted ASC 606 for open contracts on January 1, 2018 using the modified retrospective approach. As a result of the adoption of ASC 606, including guidance on contract modifications, the Company recognized a cumulative catch-up adjustment to decrease deferred revenue in the net amount of $26,507 and accumulated deficit in the net amount of $26,611 and to increase accumulated other comprehensive loss in the net amount of $104 . In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the year ended December 31, 2018 and consolidated balance sheet as of December 31, 2018 was as follows: Year Ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Collaboration and licensing revenues $ 76,869 $ 78,441 $ (1,572 ) Net loss (514,706 ) (513,134 ) (1,572 ) Net loss attributable to Intrexon (509,336 ) (507,764 ) (1,572 ) December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheet Liabilities Deferred revenue, current $ 15,554 $ 18,934 $ (3,380 ) Deferred revenue, net of current portion 54,210 48,082 6,128 Total equity Accumulated deficit (1,330,545 ) (1,355,583 ) 25,038 Accumulated other comprehensive loss (28,612 ) (28,598 ) (14 ) In February 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02"). The provisions of ASU 2018-02 allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. The amendments in ASU 2018-02 may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the United States federal corporate income tax rate in the Tax Act is recognized. The Company adopted this provision in 2018, and there was no material impact to the accompanying financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) – Scope of Modification Accounting ("ASU 2017-09") . The provisions of ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718 ("ASC 718"). An entity should account for the effects of a modification unless (a) the fair value of the modified award is the same as the fair value of the original award, (b) the vesting conditions of the modified award are the same as the vesting conditions of the original award and (c) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard effective January 1, 2018, and will apply this guidance to future modifications. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash (A Consensus of the FASB Emerging Issues Task Force) ("ASU 2016-18"). The provisions of ASU 2016-18 require amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the total beginning and ending balances for the periods presented on the statement of cash flows. The Company adopted this standard effective January 1, 2018. In accordance with the provisions of ASU 2016-18, net cash used in operating activities decreased by $6,987 and the "Cash, cash equivalents, and restricted cash" ending period balance increased by $6,987 for the year ended December 31, 2016 in the accompanying consolidated statement of cash flows. The beginning and ending period balances increased by $6,987 and $7,434 , respectively; net cash used in operating activities decreased by $419 ; and the effect of exchange rate changes on cash, cash equivalents, and restricted cash increased by $28 in the accompanying consolidated statement of cash flows for the year ended December 31, 2017 from what was previously reported in the Company's Annual Report for the period ended December 31, 2017 . In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). The provisions of ASU 2016-16 remove the prohibition in ASC Topic 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under ASC Topic 230 and other Topics. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. In February 2018, the FASB issued ASU 2018-03, Technical Corrections and Improvements to Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , to clarify certain aspects of the guidance issued in ASU 2016-01. The Company adopted this standard effective January 1, 2018, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use ("ROU") asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, ASC Topic 840 ("ASC 840"), Leases . In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842 (Leases) , and ASU 2018-11, Leases (Topic 842), Targeted Improvements ("ASU 2018-11"), which provide (i) narrow amendments to clarify how to apply certain aspects of the new lease standard, (ii) entities with an additional transition method to adopt the new standard, and (ii) lessors with a practical expedient for separating components of a contract. ASU 2018-11 specifically permits an entity to elect an additional transition method to the existing modified retrospective transition requirements. Under the new transition method, an entity could adopt the provisions of ASU No. 2016-02 by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption without adjustment to the financial statements for periods prior to adoption. Consequently, an entity's reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with the previous lease guidance in ASC 840. ASU No. 2018-11 also allows a practical expedient that permits lessors to not separate non-lease components from the associated lease component if certain conditions are present. All of these ASUs related to ASC Topic 842 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is adopting ASU 2016-02 using the modified retrospective method, upon its effective date of January 1, 2019. The Company is electing the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows the Company to carryforward the historical lease classification for all leases in effect at adoption. The Company will make an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheet and will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. Upon adoption of ASU 2016-02, the Company expects to recognize ROU assets and lease liabilities for operating leases within a range of $42,000 to $47,000 . In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under ASC 606 and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified or removed. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, but entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. This standard is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The provisions of ASU 2018-07 expand the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted no earlier than an entity's adoption date of ASC 606, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13") . The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.
Reclassifications	Reclassifications Certain insignificant reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Organization And Significant Accounting Policies [Line Items]
Summarized Financial Information of Equity Method Investments	Summarized financial data as of December 31, 2018 and 2017 , and for the years ended December 31, 2018 , 2017 , and 2016 , for the Company's equity method investments are shown in the following tables. December 31, 2018 2017 Current assets $ 17,485 $ 61,086 Noncurrent assets 31,274 13,598 Total assets 48,759 74,684 Current liabilities 4,226 6,213 Net assets $ 44,533 $ 68,471 Year Ended December 31, 2018 2017 2016 Revenues $ 557 $ 254 $ 417 Operating expenses 36,990 41,904 62,373 Operating loss (36,433 ) (41,650 ) (61,956 ) Other, net 44 (8 ) 1,535 Net loss $ (36,389 ) $ (41,658 ) $ (60,421 )
Rollforward of Allowance for Doubtful Accounts	The following table shows the activity in the allowance for doubtful receivable accounts for the years ended December 31, 2018 , 2017 , and 2016 : 2018 2017 2016 Beginning balance $ 4,631 $ 3,703 $ 2,081 Charged to operating expenses 1,779 1,217 1,963 Write offs of accounts receivable, net of recoveries (1,267 ) (289 ) (341 ) Ending balance $ 5,143 $ 4,631 $ 3,703
Estimated Useful Lives of Property, Plant and Equipment	The estimated useful lives of these assets are as follows: Years Land improvements 4–20 Buildings and building improvements 3–25 Furniture and fixtures 1–10 Equipment 1–10 Breeding stock 1–4 Computer hardware and software 1–7 Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to twenty years .
Summary of Assumptions Used in Option Pricing Model	The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2018 , 2017 and 2016 are set forth in the table below: 2018 2017 2016 Valuation assumptions Expected dividend yield 0% 0% 0% Expected volatility 55%—59% 57%—60% 59%—60% Expected term (years) 6.25 6.25 6.25 Risk-free interest rate 2.33%—3.06% 1.89%—2.27% 1.23%—2.17%
Accounting Standards Update 2014-09
Organization And Significant Accounting Policies [Line Items]
Schedule of Impact of Adoption of ASC 606	In accordance with ASC 606, the disclosure of the impacted line items upon adoption of ASC 606 on the Company's consolidated statement of operations for the year ended December 31, 2018 and consolidated balance sheet as of December 31, 2018 was as follows: Year Ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Collaboration and licensing revenues $ 76,869 $ 78,441 $ (1,572 ) Net loss (514,706 ) (513,134 ) (1,572 ) Net loss attributable to Intrexon (509,336 ) (507,764 ) (1,572 ) December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheet Liabilities Deferred revenue, current $ 15,554 $ 18,934 $ (3,380 ) Deferred revenue, net of current portion 54,210 48,082 6,128 Total equity Accumulated deficit (1,330,545 ) (1,355,583 ) 25,038 Accumulated other comprehensive loss (28,612 ) (28,598 ) (14 )

Mergers and Acquisitions (Table

Mergers and Acquisitions (Tables) - GenVec, Inc.	12 Months Ended
	Dec. 31, 2018
Business Acquisition [Line Items]
Fair Value of Consideration Transferred	The fair value of the total consideration transferred was $17,582 . The acquisition date fair value of each class of consideration transferred is presented below: Common shares $ 15,616 Warrants 1,381 Contingent consideration 585 $ 17,582
Fair Value of Assets Acquired and Liabilities Assumed	The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below: Cash and cash equivalents $ 2,054 Short-term investments 542 Trade receivables 75 Other receivables 97 Prepaid expenses and other 227 Property and equipment 250 Intangible assets 14,000 Other noncurrent assets 58 Total assets acquired 17,303 Accounts payable 2,158 Accrued compensation and benefits 1,226 Other accrued expenses 856 Other long-term liabilities 92 Deferred tax liabilities 239 Total liabilities assumed 4,571 Net assets acquired 12,732 Goodwill 4,850 Total consideration $ 17,582
Condensed Pro forma Financial Information	The following unaudited condensed pro forma financial information for the years ended December 31, 2017 and 2016, is presented as if the acquisition had been consummated on January 1, 2016: Year Ended December 31, 2017 2016 Pro Forma Revenues $ 231,213 $ 191,437 Loss before income taxes (136,966 ) (201,210 ) Net loss (134,275 ) (197,144 ) Net loss attributable to the noncontrolling interests 9,802 3,662 Net loss attributable to Intrexon (124,473 ) (193,482 )

Collaboration and Licensing R_2

Collaboration and Licensing Revenue (Tables)	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summarized Collaboration and Licensing Revenues	The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2018 , 2017 and 2016 . Year Ended December 31, 2018 2017 2016 ZIOPHARM Oncology, Inc. $ 16,298 $ 69,812 $ 33,836 Ares Trading S.A. 11,175 10,738 10,192 Oragenics, Inc. 1,353 2,020 2,752 Intrexon T1D Partners, LLC 2,502 5,968 1,908 Intrexon Energy Partners, LLC 6,929 10,665 17,552 Intrexon Energy Partners II, LLC 2,998 3,672 3,169 Genopaver, LLC 3,710 6,690 6,117 Fibrocell Science, Inc. 1,394 7,344 5,942 Persea Bio, LLC 955 946 1,278 OvaXon, LLC — 1,966 2,934 S & I Ophthalmic, LLC — 755 6,141 Harvest start-up entities (1) 14,447 15,232 4,974 Other 15,108 9,771 13,076 Total $ 76,869 $ 145,579 $ 109,871 (1) For the years ended December 31, 2018 , 2017 , and 2016 , revenue recognized from collaborations with Harvest start-up entities include Genten Therapeutics, Inc.; CRS Bio, Inc.; Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. For the years ended December 31, 2017 and 2016 , revenue recognized from collaborations with Harvest start-up entities also include Relieve Genetics, Inc.
Summary of Deferred Revenue	Deferred revenue consists of the following: December 31, 2018 2017 Collaboration and licensing agreements $ 63,284 $ 231,583 Prepaid product and service revenues 2,933 4,681 Other 3,547 133 Total $ 69,764 $ 236,397 Current portion of deferred revenue $ 15,554 $ 42,870 Long-term portion of deferred revenue 54,210 193,527 Total $ 69,764 $ 236,397
Summary of Deferred Revenue by Collaborator	The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December 31, 2018 and 2017 , including the estimated remaining performance period as of December 31, 2018 . See discussion above for significant changes to our ECCs in 2018, including ZIOPHARM and Ares Trading. Average Remaining Performance Period (Years) December 31, 2018 2017 ZIOPHARM Oncology, Inc. 0.8 $ 1,214 $ 90,496 Ares Trading S.A. 0.0 — 40,789 Oragenics, Inc. 5.4 5,810 6,719 Intrexon T1D Partners, LLC 0.0 — 8,435 Intrexon Energy Partners, LLC 5.3 10,267 15,625 Intrexon Energy Partners II, LLC 5.9 14,060 13,833 Genopaver, LLC 5.3 1,175 1,704 Fibrocell Science, Inc. 5.9 17,519 16,607 Persea Bio, LLC 6.0 2,697 3,500 Harvest start-up entities (1) 6.2 7,644 18,400 Other 2.3 2,898 14,423 Total $ 63,284 $ 230,531 (1) As of December 31, 2018 and December 31, 2017 , the balance of deferred revenue for collaborations with Harvest start-up entities includes Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. As of December 31, 2017 , the balance of deferred revenue for collaborations with Harvest start-up entities also includes: Genten Therapeutics, Inc.; CRS Bio, Inc.; and Relieve Genetics, Inc. See Note 3 for further discussion of the asset acquisition of certain Harvest entities.

Short-term Investments (Tables)

Short-term Investments (Tables)	12 Months Ended
	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments	The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value United States government debt securities $ 119,401 $ — $ (61 ) $ 119,340 Certificates of deposit 348 — — 348 Total $ 119,749 $ — $ (61 ) $ 119,688 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2017 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value United States government debt securities $ 6,000 $ — $ (2 ) $ 5,998 Certificates of deposit 275 — — 275 Total $ 6,275 $ — $ (2 ) $ 6,273

Investments in Preferred Stock

Investments in Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Investment in Preferred Stock [Abstract]
Schedule of Changes in Level 3 Investments	The following table summarizes the changes in the Level 3 investments in preferred stock during the years ended December 31, 2018 and 2017 . 2018 2017 Beginning balance $ 161,225 $ 129,545 Purchase of preferred stock — 766 Conversion of receivables to preferred stock — 3,385 Dividend income from investments in preferred stock 14,841 16,756 Net unrealized appreciation (depreciation) in the fair value of the investments in preferred stock (17,499 ) 10,773 Return of preferred stock (158,376 ) — Ending balance $ 191 $ 161,225

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2018 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, Assets United States government debt securities $ — $ 119,340 $ — $ 119,340 Equity securities 1,626 556 — 2,182 Preferred stock — — 191 191 Other — 468 — 468 Total $ 1,626 $ 120,364 $ 191 $ 122,181 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2017 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, Assets United States government debt securities $ — $ 5,998 $ — $ 5,998 Equity securities 10,537 4,563 — 15,100 Preferred stock — — 161,225 161,225 Other — 850 — 850 Total $ 10,537 $ 11,411 $ 161,225 $ 183,173
Schedule of Changes in Level 3 Liabilities	The changes in the fair value of the Level 3 liabilities during the years ended December 31, 2018 and 2017 were as follows: 2018 2017 Beginning balance $ 585 $ 2,081 Acquisition date fair value of contingent consideration liability — 585 Change in fair value of contingent consideration recognized in selling, general and administrative expenses — (2,081 ) Ending balance $ 585 $ 585

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: December 31, 2018 2017 Supplies, embryos and other production materials $ 4,729 $ 2,673 Work in process 4,391 4,767 Livestock 10,167 11,040 Feed 2,160 2,013 Total inventory $ 21,447 $ 20,493

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following: December 31, 2018 2017 Land and land improvements $ 12,490 $ 11,767 Buildings and building improvements 20,371 18,183 Furniture and fixtures 1,891 2,515 Equipment 74,555 65,863 Leasehold improvements 28,289 25,277 Breeding stock 4,582 3,832 Computer hardware and software 11,697 10,128 Trees 11,910 6,642 Construction and other assets in progress 18,880 14,113 184,665 158,320 Less: Accumulated depreciation and amortization (55,791 ) (45,646 ) Property, plant and equipment, net $ 128,874 $ 112,674

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017 , are as follows: 2018 2017 Beginning balance $ 153,289 $ 157,175 Acquisitions — 4,850 Impairment — (13,823 ) Foreign currency translation adjustments (3,704 ) 5,087 Ending balance $ 149,585 $ 153,289
Schedule of Intangible Assets	Intangible assets consist of the following as of December 31, 2018 : Weighted Average Useful Life (Years) Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how 15.5 $ 152,482 $ (35,133 ) $ 117,349 Customer relationships 6.5 10,700 (7,565 ) 3,135 Trademarks 9.3 6,800 (3,341 ) 3,459 In-process research and development 5,348 — 5,348 Total $ 175,330 $ (46,039 ) $ 129,291 Intangible assets consist of the following as of December 31, 2017 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 263,615 $ (44,954 ) $ 218,661 Customer relationships 10,700 (6,383 ) 4,317 Trademarks 6,800 (2,567 ) 4,233 In-process research and development 5,666 — 5,666 Total $ 286,781 $ (53,904 ) $ 232,877
Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense	Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows: 2019 $ 11,966 2020 11,863 2021 11,675 2022 10,676 2023 9,798 Thereafter 67,965 Total $ 123,943

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	Long-term debt consists of the following: December 31, 2018 2017 Convertible debt $ 203,391 $ — Notes payable 4,551 5,010 Royalty-based financing 2,085 2,132 Other 1,767 895 Long-term debt 211,794 8,037 Less current portion 559 502 Long-term debt, less current portion $ 211,235 $ 7,535
Schedule of Maturities of Long-Term Debt	Future maturities of long-term debt are as follows: 2019 $ 559 2020 30,843 2021 25,405 2022 420 2023 201,442 Thereafter 2,939 Total $ 261,608

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Components of Loss Before Income Taxes	The components of loss before income taxes are presented below: Year Ended December 31, 2018 2017 2016 Domestic $ (443,337 ) $ (71,343 ) $ (157,067 ) Foreign (92,897 ) (58,357 ) (37,084 ) Loss before income taxes $ (536,234 ) $ (129,700 ) $ (194,151 )
Components of Income Tax Expense (Benefit)	The components of income tax expense (benefit) are presented below: Year Ended December 31, 2018 2017 2016 United States federal income taxes: Current $ (31 ) $ 27 $ (17 ) Deferred (11,855 ) (523 ) 1,396 Foreign income taxes: Current (332 ) (379 ) (393 ) Deferred (5,068 ) (2,269 ) (5,177 ) State income taxes: Current 113 — — Deferred (4,355 ) 264 314 Income tax benefit $ (21,528 ) $ (2,880 ) $ (3,877 )
Schedule of Effective Income Tax Rate Reconciliation	Income tax benefit for the years ended December 31, 2018 , 2017 and 2016 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% for 2018 , and 34% for years prior to 2018, to loss before income taxes as a result of the following: 2018 2017 2016 Computed statutory income tax benefit $ (112,609 ) $ (44,098 ) $ (66,011 ) State and provincial income tax benefit, net of federal income taxes (24,724 ) (3,294 ) (7,905 ) Nondeductible stock based compensation 1,834 4,147 3,321 Nondeductible officer compensation 294 476 — Gain on dividend distribution of AquaBounty common stock — 3,965 — Impairment of goodwill — 4,700 — Research and development tax incentives (1,088 ) (1,166 ) (6,350 ) Acquisition and internal restructuring transaction costs 52 354 571 Provisional impact of the Tax Act — 85,288 — Enacted changes in foreign tax rates and foreign tax reforms — 2,138 — Reacquired in-process research and development 2,696 — — Change in deferred state tax rate 8,666 — — United States-foreign rate differential 3,017 5,410 3,463 Other, net (486 ) (64 ) 1,485 (122,348 ) 57,856 (71,426 ) Change in valuation allowance for deferred tax assets 100,820 (60,736 ) 67,549 Total income tax benefit $ (21,528 ) $ (2,880 ) $ (3,877 )
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that comprise the deferred tax assets and liabilities as of December 31, 2018 and 2017 , are as follows: 2018 2017 Deferred tax assets Allowance for doubtful accounts $ 1,490 $ 1,300 Inventory 614 489 Equity securities and investments in affiliates 30,241 17,510 Intangible assets 71,205 — Accrued liabilities 4,412 3,131 Stock-based compensation 29,297 26,936 Deferred revenue 16,297 61,785 Research and development tax credits 11,597 11,385 Net operating and capital loss carryforwards 148,411 111,453 Total deferred tax assets 313,564 233,989 Less: Valuation allowance 308,113 215,582 Net deferred tax assets 5,451 18,407 Deferred tax liabilities Property, plant and equipment 528 237 Intangible assets — 33,790 Long-term debt 12,136 — Total deferred tax liabilities 12,664 34,027 Net deferred tax liabilities $ (7,213 ) $ (15,620 )
Summary of Valuation Allowance	Activity within the valuation allowance for deferred tax assets during the years ended December 31, 2018 , 2017 and 2016 was as follows: 2018 2017 2016 Valuation allowance at beginning of year $ 215,582 $ 256,165 $ 190,174 Increase (decrease) in valuation allowance as a result of Mergers and acquisitions, net 418 — (1,416 ) Current year operations 122,853 26,619 67,549 Adoption of ASC 606 (7,477 ) — — Adoption of ASU 2016-09 — 17,843 — Provisional impact of the Tax Act — (87,473 ) — Equity component of long-term debt (13,367 ) — — Change in deferred state tax rate (8,666 ) — — Changes in foreign tax rates and foreign tax reforms — 1,327 — Foreign currency translation adjustment (1,230 ) 1,101 (142 ) Valuation allowance at end of year $ 308,113 $ 215,582 $ 256,165

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss are as follows: December 31, 2018 2017 Unrealized loss on investments $ (61 ) $ (2 ) Loss on foreign currency translation adjustments (28,551 ) (15,552 ) Total accumulated other comprehensive loss $ (28,612 ) $ (15,554 )

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-based Compensation Expense	Stock-based compensation costs included in the consolidated statements of operations are presented below: Year Ended December 31, 2018 2017 2016 Cost of products $ 78 $ 116 $ 81 Cost of services 237 322 274 Research and development 9,676 9,336 9,251 Selling, general and administrative 26,305 31,802 32,596 Total $ 36,296 $ 41,576 $ 42,202
Schedule of Stock Option Activity	Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2015 11,043,528 $ 32.66 8.49 Granted 4,644,860 29.39 Exercised (1,210,840 ) (15.83 ) Forfeited (2,760,809 ) (40.34 ) Expired (76,356 ) (37.81 ) Balances at December 31, 2016 11,640,383 31.25 8.21 Granted 3,920,950 21.47 Adjustment due to dividend (Note 14) 46,766 31.11 Exercised (149,429 ) (6.37 ) Forfeited (3,797,105 ) (28.37 ) Expired (278,818 ) (33.18 ) Balances at December 31, 2017 11,382,747 28.99 7.32 Granted 1,470,339 14.26 Exercised (45,159 ) (6.59 ) Forfeited (929,596 ) (21.48 ) Expired (785,268 ) (26.25 ) Balances at December 31, 2018 11,093,063 27.95 6.81 Exercisable at December 31, 2018 7,002,519 30.37 5.97
Summary of Information About Stock Options Outstanding	The following table summarizes additional information about stock options outstanding as of December 31, 2018 : Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 3.17 — $ 19.52 1,973,818 $ 13.70 7.54 $ 169 833,007 $ 12.80 4.85 $ 169 $ 19.85 — $ 20.94 1,914,763 20.93 7.99 — 500,263 20.92 7.67 — $ 21.00 — $ 27.08 2,057,126 23.29 7.26 — 1,248,370 23.01 6.69 — $ 27.10 — $ 29.56 2,666,109 29.19 5.28 — 2,593,151 29.20 5.23 — $ 29.58 — $ 65.08 2,481,247 47.24 6.59 — 1,827,728 47.65 6.54 — 11,093,063 $ 27.95 6.81 $ 169 7,002,519 $ 30.37 5.97 $ 169 The following table summarizes additional information about stock options outstanding as of December 31, 2017 : Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 2.64 — $ 9.30 453,371 $ 7.06 3.94 $ 2,020 453,371 $ 7.06 3.94 $ 2,020 $ 12.50 — $ 21.38 3,158,121 20.58 8.74 — 456,942 19.52 7.13 — $ 21.43 — $ 28.81 3,399,721 25.55 6.91 — 1,804,401 25.86 5.69 — $ 28.88 — $ 40.99 2,751,716 32.07 6.70 — 1,732,250 31.51 6.32 — $ 41.41 — $ 65.08 1,619,818 53.52 7.42 — 859,733 53.07 7.38 — 11,382,747 $ 28.99 7.32 $ 2,020 5,306,697 $ 29.96 6.14 $ 2,020
Schedule of Restricted Stock Unit Activity	RSU activity was a follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2017 — $ — 0.00 Granted 1,069,126 13.84 Vested (25,000 ) (15.82 ) Forfeited (73,785 ) (13.47 ) Balances at December 31, 2018 970,341 13.82 1.43

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments Under Noncancelable Operating Leases	As of December 31, 2018 , future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows: 2019 $ 9,182 2020 9,910 2021 9,127 2022 8,305 2023 7,229 Thereafter 34,157 Total $ 77,910

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss per Share	The following table presents the computation of basic and diluted net loss per share: 2018 2017 2016 Historical net loss per share: Numerator: Net loss attributable to Intrexon $ (509,336 ) $ (117,018 ) $ (186,612 ) Denominator: Weighted average shares outstanding, basic and diluted 129,521,731 119,998,826 117,983,836 Net loss attributable to Intrexon per share, basic and diluted $ (3.93 ) $ (0.98 ) $ (1.58 )
Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share	The following potentially dilutive securities as of December 31, 2018 , 2017 , and 2016 , have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive: December 31, 2018 2017 2016 Convertible debt 18,955,668 — — Options 11,093,063 11,382,747 11,640,383 Restricted stock units 970,341 — — Warrants 133,264 133,264 — Total 31,152,336 11,516,011 11,640,383

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information (Unaudited)	The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. Three Months Ended March 31, June 30, September 30, December 31, 2018 (1) Total revenues $ 39,666 $ 45,275 $ 32,448 $ 43,185 Operating loss (52,522 ) (49,735 ) (66,471 ) (336,882 ) Net loss (47,409 ) (66,829 ) (58,746 ) (341,722 ) Net loss attributable to Intrexon (46,165 ) (65,382 ) (57,324 ) (340,465 ) Net loss attributable to Intrexon per share, basic and diluted $ (0.36 ) $ (0.51 ) $ (0.44 ) $ (2.59 ) (1) During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5 ). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11 ). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17 ). Three Months Ended March 31, June 30, September 30, December 31, 2017 (1) Total revenues $ 53,504 $ 54,433 $ 46,016 $ 77,028 Operating loss (31,381 ) (35,270 ) (44,747 ) (26,492 ) Net loss (32,377 ) (19,662 ) (40,836 ) (33,945 ) Net loss attributable to Intrexon (31,399 ) (18,664 ) (39,689 ) (27,266 ) Net loss attributable to Intrexon per share, basic and diluted $ (0.26 ) $ (0.16 ) $ (0.33 ) $ (0.23 ) (1) During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5 ). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11 ).

Organization and Basis of Pre_2

Organization and Basis of Presentation - Additional Information (Details) $ in Thousands	Dec. 31, 2018USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Cash, cash equivalents, and short-term investments	$ 222,456
AquaBounty Technologies, Inc.
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Parent ownership interest	55.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2018USD ($)		Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)		Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2018USD ($)segment	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jan. 01, 2019USD ($)	Jul. 31, 2018	Jan. 01, 2018USD ($)	Dec. 31, 2015USD ($)
Organization And Significant Accounting Policies [Line Items]
Research and development commitments with third parties not incurred	$ 11,853					$ 10,682					$ 11,853	$ 10,682
Maturity period of highly liquid investment											3 months
Cash equivalent investments in highly liquid money market accounts	40,155					43,012					$ 40,155	43,012
Fair value of financial assets measured at fair value on a recurring basis	122,181					183,173					122,181	183,173
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock											(30,200)	2,586	$ (58,894)
Maximum risk of loss related to the identified VIEs	21,219					185,261					$ 21,219	185,261
Number of segments | segment											1
Property, plant and equipment, net	128,874					112,674					$ 128,874	112,674
Revenues	43,185	[1]	$ 32,448	$ 45,275	$ 39,666	77,028	[2]	$ 46,016	$ 54,433	$ 53,504
Net cash used in operating activities											(124,240)	(103,720)	(48,988)
Cash, cash equivalents, and restricted cash	110,182					$ 75,545					110,182	75,545	69,594				$ 135,782
Effect of exchange rate changes on cash, cash equivalents, and restricted cash											295	$ 1,055	(873)
Oragenics, Inc.
Organization And Significant Accounting Policies [Line Items]
Company's ownership percentage						29.40%						29.40%
Equity securities | Oragenics, Inc.
Organization And Significant Accounting Policies [Line Items]
Fair value of financial assets measured at fair value on a recurring basis						$ 3,085						$ 3,085
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock												(4,159)	(10,523)
Foreign Countries
Organization And Significant Accounting Policies [Line Items]
Property, plant and equipment, net	$ 16,839					21,837					16,839	21,837
Revenues											$ 11,945	$ 17,605	$ 11,969
Minimum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset											3 years
Maximum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset											21 years
Intrexon Equity Plans
Organization And Significant Accounting Policies [Line Items]
Expected dividend yield											0.00%	0.00%	0.00%
Accounting Standards Update 2014-09
Organization And Significant Accounting Policies [Line Items]
Cumulative effect of adoption of ASC 606																$ 26,507
Accounting Standards Update 2016-18
Organization And Significant Accounting Policies [Line Items]
Net cash used in operating activities												$ 419	$ 6,987
Cash, cash equivalents, and restricted cash						$ 7,434						7,434	$ 6,987
Effect of exchange rate changes on cash, cash equivalents, and restricted cash												$ 28
Accumulated Deficit | Accounting Standards Update 2014-09
Organization And Significant Accounting Policies [Line Items]
Cumulative effect of adoption of ASC 606																26,611
Accumulated Other Comprehensive Loss | Accounting Standards Update 2014-09
Organization And Significant Accounting Policies [Line Items]
Cumulative effect of adoption of ASC 606																$ (104)
Subsequent Event | Accounting Standards Update 2016-02 | Minimum
Organization And Significant Accounting Policies [Line Items]
Right-of-use assets for operating leases														$ 42,000
Operating lease, liability														42,000
Subsequent Event | Accounting Standards Update 2016-02 | Maximum
Organization And Significant Accounting Policies [Line Items]
Right-of-use assets for operating leases														47,000
Operating lease, liability														$ 47,000
Collaborations and licenses
Organization And Significant Accounting Policies [Line Items]
Required notice period for voluntary termination of collaborative agreement											90 days
Products and services revenues
Organization And Significant Accounting Policies [Line Items]
Product and service revenues, standard payment terms											30 days
3.5% Convertible Notes Due 2023
Organization And Significant Accounting Policies [Line Items]
Debt instrument, interest rate, stated percentage															3.50%
[1]	During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17).
[2]	During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summarized Financial Data of Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2018		Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017		Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity Method Investment, Summarized Financial Information, Gross Profit (Loss) [Abstract]
Operating expenses											$ 666,184	$ 368,871	$ 316,092
Operating loss	$ (336,882)	[1]	$ (66,471)	$ (49,735)	$ (52,522)	$ (26,492)	[2]	$ (44,747)	$ (35,270)	$ (31,381)	(505,610)	(137,890)	(125,166)
Other, net											(19,016)	22,473	(47,865)
Equity Method Investments
Equity Method Investment, Summarized Financial Information, Assets [Abstract]
Current assets	17,485					61,086					17,485	61,086
Noncurrent assets	31,274					13,598					31,274	13,598
Total assets	48,759					74,684					48,759	74,684
Equity Method Investment, Summarized Financial Information, Liabilities [Abstract]
Current liabilities	4,226					6,213					4,226	6,213
Net assets	$ 44,533					$ 68,471					44,533	68,471
Equity Method Investment, Summarized Financial Information, Gross Profit (Loss) [Abstract]
Revenues											557	254	417
Operating expenses											36,990	41,904	62,373
Operating loss											(36,433)	(41,650)	(61,956)
Other, net											44	(8)	1,535
Net loss											$ (36,389)	$ (41,658)	$ (60,421)
[1]	During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17).
[2]	During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Rollforward of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Allowance for Doubtful Accounts
Beginning balance	$ 4,631	$ 3,703	$ 2,081
Charged to operating expenses	1,779	1,217	1,963
Write offs of accounts receivable, net of recoveries	(1,267)	(289)	(341)
Ending balance	$ 5,143	$ 4,631	$ 3,703

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2018
Minimum | Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Minimum | Building and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	3 years
Minimum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Maximum | Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	20 years
Maximum | Building and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	25 years
Maximum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	10 years
Maximum | Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	10 years
Maximum | Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Maximum | Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	20 years

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details) - Intrexon Equity Plans	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility, minimum	55.00%	57.00%	59.00%
Expected volatility, maximum	59.00%	60.00%	60.00%
Expected term (years)	6 years 3 months	6 years 3 months	6 years 3 months
Risk-free interest rate, minimum	2.33%	1.89%	1.23%
Risk-free interest rate, maximum	3.06%	2.27%	2.17%

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Schedule of Impact of Adoption of ASC 606 (Details) - USD ($) $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2018		Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017		Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues											$ 160,574	$ 230,981	$ 190,926
Net loss	$ (341,722)	[1]	$ (58,746)	$ (66,829)	$ (47,409)	$ (33,945)	[2]	$ (40,836)	$ (19,662)	$ (32,377)	(514,706)	(126,820)	(190,274)
Net loss attributable to Intrexon	(340,465)	[1]	$ (57,324)	$ (65,382)	$ (46,165)	(27,266)	[2]	$ (39,689)	$ (18,664)	$ (31,399)	(509,336)	(117,018)	(186,612)
Current portion of deferred revenue	15,554					42,870					15,554	42,870
Long-term portion of deferred revenue	54,210					193,527					54,210	193,527
Accumulated deficit	(1,330,545)					(847,820)					(1,330,545)	(847,820)
Accumulated other comprehensive loss	(28,612)					$ (15,554)					(28,612)	(15,554)
Collaborations and licenses
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues											76,869	$ 145,579	$ 109,871
Accounting Standards Update 2014-09 | Balances Without Adoption of ASC 606
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss											(513,134)
Net loss attributable to Intrexon											(507,764)
Current portion of deferred revenue	18,934										18,934
Long-term portion of deferred revenue	48,082										48,082
Accumulated deficit	(1,355,583)										(1,355,583)
Accumulated other comprehensive loss	(28,598)										(28,598)
Accounting Standards Update 2014-09 | Balances Without Adoption of ASC 606 | Collaborations and licenses
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues											78,441
Accounting Standards Update 2014-09 | Effect of Change
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss											(1,572)
Net loss attributable to Intrexon											(1,572)
Current portion of deferred revenue	(3,380)										(3,380)
Long-term portion of deferred revenue	6,128										6,128
Accumulated deficit	25,038										25,038
Accumulated other comprehensive loss	$ (14)										(14)
Accounting Standards Update 2014-09 | Effect of Change | Collaborations and licenses
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues											$ (1,572)
[1]	During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17).
[2]	During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Mergers and Acquisitions - Asse

Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Aug. 31, 2018
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition		$ 30,000	$ 0	$ 0
Cash received in asset acquisition		15,500	(14,219)	(7,244)
Investments in affiliates		18,859	18,870
Deferred revenue		69,764	236,397
Reacquisition of in-process research and development		$ 236,748	$ 0	$ 0
Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Cash received in asset acquisition	$ 15,500
ActoBio Therapeutics Inc. | Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition	$ 30,000
CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc.
Business Acquisition [Line Items]
Investments in affiliates					$ 4,303
Ownership interest	100.00%
Deferred revenue	$ 10,078
Reacquisition of in-process research and development	$ 8,721

Mergers and Acquisitions - GenV

Mergers and Acquisitions - GenVec - Fair Value of Consideration Transferred (Details) - GenVec, Inc. $ in Thousands	1 Months Ended
	Jun. 30, 2017USD ($)
Business Acquisition [Line Items]
Common shares	$ 15,616
Warrants	1,381
Contingent consideration	585
Total consideration transferred	$ 17,582

Mergers and Acquisitions - Ge_2

Mergers and Acquisitions - GenVec - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 149,585	$ 153,289		$ 157,175
GenVec, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents			$ 2,054
Short-term investments			542
Trade receivables			75
Other receivables			97
Prepaid expenses and other			227
Property and equipment			250
Intangible assets			14,000
Other noncurrent assets			58
Total assets acquired			17,303
Accounts payable			2,158
Accrued compensation and benefits			1,226
Other accrued expenses			856
Other long-term liabilities			92
Deferred tax liabilities			239
Total liabilities assumed			4,571
Net assets acquired			12,732
Goodwill			4,850
Total consideration			$ 17,582

Mergers and Acquisitions - Ge_3

Mergers and Acquisitions - GenVec - Additional Information (Details) - GenVec, Inc. - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired	100.00%
Business combination, consideration paid, shares issued	684,240
Collaboration agreement, percent of collaboration payments	50.00%
Business combination, period subsequent to acquisition during which a portion of collaboration payments received will be paid to former stockholders of acquired entity	3 years
Expected useful life of intangible asset	11 years
Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related cost		$ 507	$ 12

Mergers and Acquisitions - Ge_4

Mergers and Acquisitions - GenVec - Pro Forma Financial Information (Details) - GenVec, Inc. - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenues	$ 231,213	$ 191,437
Loss before income taxes	(136,966)	(201,210)
Net loss	(134,275)	(197,144)
Net loss attributable to the noncontrolling interests	9,802	3,662
Net loss attributable to Intrexon	$ (124,473)	$ (193,482)

Investments in Joint Ventures -

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2018USD ($)board_seat	Dec. 31, 2017USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ 18,859,000	$ 18,870,000
Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Maximum additional capital contributions committed		$ 25,000,000
Additional capital contributions committed, remaining commitment			$ 4,938,000
Total number of seats on the joint venture's governing board | board_seat			5
Total number of seats on the joint venture's governing board, internally selected | board_seat			2
Total number of seats on the joint venture's governing board, externally selected | board_seat			3
Investor | Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Capital contribution		$ 25,000,000
Maximum additional capital contributions committed		25,000,000
Other accrued liabilities | Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ (656,000)	$ (444,000)
Intrexon Energy Partners II, LLC | Collaborations and licenses
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 18,000,000
Intrexon Energy Partners, LLC | Collaborations and licenses
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value		$ 25,000,000

Investments in Joint Ventures_2

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2018USD ($)board_seat	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 18,859,000	$ 18,870,000
Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest				50.00%
Maximum additional capital contributions committed				$ 10,000,000
Total number of seats on the joint venture's governing board | board_seat		5
Total number of seats on the joint venture's governing board, internally selected | board_seat		1
Total number of seats on the joint venture's governing board, externally selected | board_seat		4
Investor | Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest				50.00%
Capital contribution	$ 18,000,000
Maximum additional capital contributions committed				$ 10,000,000
All Investors | Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	4,000,000
Other accrued liabilities | Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ (50,000)
Investments in affiliates | Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ 572,000
Intrexon Energy Partners II, LLC | Collaborations and licenses
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 18,000,000

Investments in Joint Ventures_3

Investments in Joint Ventures - EnviroFlight - Additional Information (Details) - USD ($)	1 Months Ended		12 Months Ended			34 Months Ended
	Oct. 31, 2016	Feb. 29, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2018
Schedule Of Investments In Joint Venture [Line Items]
Cash paid in asset acquisition			$ (15,500,000)	$ 14,219,000	$ 7,244,000
Shares issued in asset acquisition or for reacquired in-process research and development			159,323,000		4,401,000
Contingent consideration assumed in asset acquisition			0	0	3,660,000
Stock issued as payment for contingent consideration			0	0	1,583,000
Investment			18,859,000	18,870,000		$ 18,859,000
EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Cash paid in asset acquisition		$ 4,244,000
Shares issued in asset acquisition or for reacquired in-process research and development, shares		136,340
Shares issued in asset acquisition or for reacquired in-process research and development		$ 4,401,000
Contingent consideration assumed in asset acquisition		3,660,000
Capital contribution		$ 3,000,000				17,000,000
Membership interest		50.00%
Estimated fair value of investment		$ 5,425,000
Shares issued as payment for contingent or deferred consideration, shares	59,337
Stock issued as payment for contingent consideration	$ 1,583,000
Contingent consideration for commercial milestones payable in common stock, maximum		$ 4,000,000
Investor | EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution						17,000,000
Membership interest		50.00%
Patents, developed technologies and know-how | EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Estimated fair value of developed technology acquired		$ 9,880,000
Expected useful life of intangible asset		21 years
Investments in affiliates | EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			16,720,000	7,092,000		16,720,000
Significant Unobservable Inputs (Level 3)
Schedule Of Investments In Joint Venture [Line Items]
Fair value of liability			585,000	$ 585,000	$ 2,081,000	585,000
Significant Unobservable Inputs (Level 3) | EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Fair value of liability			$ 0			$ 0

Investments in Joint Ventures_4

Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)	1 Months Ended		12 Months Ended
	Nov. 30, 2018USD ($)shares	Mar. 31, 2016USD ($)	Dec. 31, 2018USD ($)board_seat	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Oct. 31, 2018USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Shares issued in asset acquisition or for reacquired in-process research and development			$ 159,323,000		$ 4,401,000
Deferred revenue			69,764,000	$ 236,397,000
Reacquisition of in-process research and development			236,748,000	0	$ 0
Collaborations and licenses
Schedule Of Investments In Joint Venture [Line Items]
Deferred revenue			$ 63,284,000	$ 231,583,000
Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	100.00%	50.00%
Maximum additional capital contributions committed		$ 5,000,000
Total number of seats on the joint venture's governing board, internally selected | board_seat			2
Total number of seats on the joint venture's governing board, externally selected | board_seat			3
Shares issued in asset acquisition or for reacquired in-process research and development, shares | shares	1,933,737
Shares issued in asset acquisition or for reacquired in-process research and development	$ 18,970,000
Deferred revenue						$ 8,517,000
Reacquisition of in-process research and development	$ 10,453,000
Investor | Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Capital contribution		$ 10,000,000
Maximum additional capital contributions committed		5,000,000
Intrexon T1D Partners, LLC | Collaborations and licenses
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value		$ 10,000,000

Investments in Joint Ventures_5

Investments in Joint Ventures - Other Joint Ventures - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Investments In Joint Venture [Line Items]
Return of investment in affiliate		$ 2,598	$ 0	$ 0
S & I Opthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Return of investment in affiliate	$ 2,598

Collaboration and Licensing R_3

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		$ 160,574	$ 230,981	$ 190,926
Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		76,869	145,579	109,871
ZIOPHARM Oncology, Inc. | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		16,298	69,812	33,836
Ares Trading S.A. | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		11,175	10,738	10,192
Oragenics, Inc. | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		1,353	2,020	2,752
Intrexon T1D Partners, LLC | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		2,502	5,968	1,908
Intrexon Energy Partners, LLC | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		6,929	10,665	17,552
Intrexon Energy Partners II, LLC | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		2,998	3,672	3,169
Genopaver, LLC | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		3,710	6,690	6,117
Fibrocell Science, Inc. | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		1,394	7,344	5,942
Persea Bio, LLC | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		955	946	1,278
OvaXon, LLC | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		0	1,966	2,934
S & I Ophthalmic, LLC | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		0	755	6,141
Harvest Start-Up Entities | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues	[1]	14,447	15,232	4,974
Other | Collaborations and licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		$ 15,108	$ 9,771	$ 13,076
[1]	For the years ended December 31, 2018, 2017, and 2016, revenue recognized from collaborations with Harvest start-up entities include Genten Therapeutics, Inc.; CRS Bio, Inc.; Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. For the years ended December 31, 2017 and 2016, revenue recognized from collaborations with Harvest start-up entities also include Relieve Genetics, Inc.

Collaboration and Licensing R_4

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 69,764	$ 236,397
Current portion of deferred revenue	15,554	42,870
Long-term portion of deferred revenue	54,210	193,527
Collaborations and licenses
Deferred Revenue Arrangement [Line Items]
Deferred revenue	63,284	231,583
Prepaid product and service revenues
Deferred Revenue Arrangement [Line Items]
Deferred revenue	2,933	4,681
Other
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 3,547	$ 133

Collaboration and Licensing R_5

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			$ 230,531
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 63,284
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			90,496
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		9 months 18 days
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 1,214
Ares Trading S.A. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			40,789
Ares Trading S.A. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		0 years
Ares Trading S.A. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 0
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			6,719
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		5 years 4 months 24 days
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 5,810
Intrexon T1D Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			8,435
Intrexon T1D Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		0 years
Intrexon T1D Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 0
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			15,625
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		5 years 3 months 18 days
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 10,267
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			13,833
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		5 years 10 months 24 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 14,060
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			1,704
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		5 years 3 months 18 days
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 1,175
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			16,607
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		5 years 10 months 24 days
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 17,519
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			3,500
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		6 years
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 2,697
Harvest Start-Up Entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	[1]		18,400
Harvest Start-Up Entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)	[1]	6 years 2 months 12 days
Harvest Start-Up Entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	[1]	$ 7,644
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			$ 14,423
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		2 years 3 months 18 days
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 2,898
[1]	As of December 31, 2018 and December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities includes Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. As of December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities also includes: Genten Therapeutics, Inc.; CRS Bio, Inc.; and Relieve Genetics, Inc. See Note 3 for further discussion of the asset acquisition of certain Harvest entities.

Collaboration and Licensing R_6

Collaboration and Licensing Revenue - Additional Information (Details)

May 25, 2018

Dec. 31, 2018USD ($)shares

Nov. 30, 2018USD ($)shares

Oct. 31, 2018USD ($)quarterly_installmentproduct

Dec. 31, 2017USD ($)

Nov. 30, 2017USD ($)

Sep. 30, 2016USD ($)

Jun. 30, 2016USD ($)shares

Mar. 31, 2016USD ($)

Dec. 31, 2015USD ($)shares

Sep. 30, 2015USD ($)

Jun. 30, 2015USD ($)

May 31, 2015USD ($)target

Dec. 31, 2014USD ($)

Mar. 31, 2014USD ($)

Jun. 30, 2013USD ($)shares

Mar. 31, 2013USD ($)

Feb. 28, 2013

Oct. 31, 2012USD ($)shares

Jun. 30, 2012USD ($)shares

Jan. 31, 2011USD ($)shares

May 31, 2016

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Sep. 30, 2018USD ($)

Jun. 30, 2018

Jan. 01, 2018USD ($)

Collaboration Agreements [Line Items]

Revenues

$ 160,574,000

$ 230,981,000

$ 190,926,000

Fair value of assets

$ 122,181,000

$ 183,173,000

122,181,000

183,173,000

Deferred revenue

69,764,000

236,397,000

69,764,000

236,397,000

Reacquisition of in-process research and development

236,748,000

0

0

Shares issued in asset acquisition or for reacquired in-process research and development

159,323,000

4,401,000

Collaborations and licenses

Collaboration Agreements [Line Items]

Revenues

76,869,000

145,579,000

109,871,000

Deferred revenue

63,284,000

231,583,000

$ 63,284,000

231,583,000

Required notice period for voluntary termination of collaborative agreement

90 days

Licensing agreement between ZIOPHARM and Precigen 2018

Collaboration Agreements [Line Items]

Period after which additional products to be developed and commercialized

2 years

License agreement, percentage of development costs for which responsible

20.00%

License agreement, percentage of operating profits to be received

20.00%

License agreement, annual fee

$ 100,000

License agreement, reimbursement of historical costs, number of quarterly installments | quarterly_installment

4

Milestone payments required upon successful achievement, aggregated

$ 210,000,000

License agreement, royalty due, aggregated

$ 100,000,000

License agreement, percentage of sublicensing income

20.00%

License agreement, termination, period following triggering event

12 years

Maximum | Licensing agreement between ZIOPHARM and Precigen 2018

Collaboration Agreements [Line Items]

License agreement, reimbursement of historical costs

$ 1,000,000

Milestone payments required upon successful achievement, per product

$ 52,500,000

License agreement, number of exclusively licensed products | product

4

Transition period during which costs will be reimbursed

1 year

ZIOPHARM Oncology, Inc. | Licensing agreement between ZIOPHARM and Precigen 2018

Collaboration Agreements [Line Items]

License agreement, percentage of development costs for which responsible

80.00%

License agreement, percentage of operating profits to be received

80.00%

License agreement, royalty due, aggregated

$ 50,000,000

Fibrocell Science, Inc.

Collaboration Agreements [Line Items]

Stockholders' equity, reverse stock split

1-for-5

Stockholders' equity reverse stock split conversion ratio

0.2

ZIOPHARM Oncology, Inc.

Collaboration Agreements [Line Items]

Reacquisition of in-process research and development

109,047,000

ZIOPHARM Oncology, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received (in shares) | shares

3,636,926

3,636,926

Collaborative agreement, consideration received, value

100,000

$ 120,000,000

$ 10,000,000

$ 18,330,000

$ 17,457,000

Revenues

$ 16,298,000

69,812,000

33,836,000

Royalty rate as a percentage of net profit

20.00%

50.00%

Collaborative arrangement consideration received, number of preferred shares (in shares) | shares

100,000

Deferred revenue

$ 51,084,000

ZIOPHARM Oncology, Inc. | Transfer of clinical product candidate(s) | Collaborations and licenses

Collaboration Agreements [Line Items]

Revenues

1,115,000

ZIOPHARM Oncology, Inc. | Single performance obligation | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 16,342,000

ZIOPHARM Oncology, Inc. | Milestone consideration | Collaborations and licenses

Collaboration Agreements [Line Items]

Cumulative effect of adoption of ASC 606

$ 873,000

ZIOPHARM Oncology, Inc. | ZIOPHARM ECC 2 | Collaborations and licenses

Collaboration Agreements [Line Items]

Revenues

28,943,000

ZIOPHARM Oncology, Inc. | Contract modification consideration | Collaborations and licenses

Collaboration Agreements [Line Items]

Cumulative effect of adoption of ASC 606

$ 32,422,000

ZIOPHARM Oncology, Inc. | Reacquired in-process research & development | Collaborations and licenses

Collaboration Agreements [Line Items]

Deferred revenue

49,329,000

ZIOPHARM Oncology, Inc. | Transition services | Collaborations and licenses

Collaboration Agreements [Line Items]

Deferred revenue

1,855,000

1,755,000

ZIOPHARM Oncology, Inc. | Historical cost reimbursement | Collaborations and licenses

Collaboration Agreements [Line Items]

Revenues

500,000

Ares Trading S.A.

Collaboration Agreements [Line Items]

Reacquisition of in-process research and development

$ 108,527,000

Shares issued in asset acquisition or for reacquired in-process research and development, shares | shares

20,640,119

Shares issued in asset acquisition or for reacquired in-process research and development

$ 140,353,000

Royalty percentage to be paid to other party

0.1

Ares Trading S.A. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 115,000,000

Revenues

$ 11,175,000

10,738,000

10,192,000

Collaborative agreement, consideration receivable, minimum targets required | target

2

Ares Trading S.A. | Reacquired in-process research & development | Collaborations and licenses

Collaboration Agreements [Line Items]

Deferred revenue

$ 31,826,000

Ares Trading S.A. | Research & development services | Collaborations and licenses

Collaboration Agreements [Line Items]

Deferred revenue

$ 10,000,000

Collaborative agreement, consideration receivable, collection period

2 years

Ares Trading S.A. | ZIOPHARM Oncology, Inc.

Collaboration Agreements [Line Items]

Collaboration agreement, percent of collaboration payments

50.00%

Ares Trading S.A. | ZIOPHARM Oncology, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Payments to related parties

$ 57,500,000

Oragenics, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received (in shares) | shares

439,243

Collaborative agreement, consideration received, value

$ 6,588,000

Revenues

$ 1,353,000

2,020,000

2,752,000

Royalty rate as a percentage of net profit

25.00%

Required notice period for voluntary termination of collaborative agreement

90 days

90 days

Collaborative agreement, consideration received, value of convertible promissory note

$ 5,000,000

Oragenics, Inc. | Maximum | Oragenics ECC

Collaboration Agreements [Line Items]

Milestone payments required upon successful achievement, one-time

$ 35,000,000

Oragenics, Inc. | Maximum | Oragenics ECC2

Collaboration Agreements [Line Items]

Milestone payments required upon successful achievement, one-time

$ 37,500,000

Intrexon T1D Partners, LLC | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 10,000,000

Revenues

2,502,000

5,968,000

1,908,000

Genten Therapeutics, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 3,000,000

Collaborative agreement, consideration received, cash

1,500,000

CRS Bio, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 2,100,000

Relieve Genetics, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

4,333,000

Intrexon Energy Partners, LLC | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 25,000,000

Revenues

6,929,000

10,665,000

17,552,000

Required notice period for voluntary termination of collaborative agreement

90 days

Intrexon Energy Partners II, LLC | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 18,000,000

Revenues

2,998,000

3,672,000

3,169,000

Required notice period for voluntary termination of collaborative agreement

90 days

Exotech Bio, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 5,000,000

Required notice period for voluntary termination of collaborative agreement

90 days

AD Skincare, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 4,333,000

Required notice period for voluntary termination of collaborative agreement

90 days

AD Skincare, Inc. | Maximum | Collaborations and licenses

Collaboration Agreements [Line Items]

Milestone payments required upon successful achievement, per product

$ 2,000,000

Milestone payments required upon successful achievement, one-time

$ 17,000,000

Genopaver, LLC | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 3,000,000

Revenues

3,710,000

6,690,000

6,117,000

Required notice period for voluntary termination of collaborative agreement

90 days

Fibrocell Science, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received (in shares) | shares

82,919

87,835

Collaborative agreement, consideration received, value

$ 10,000,000

$ 7,612,000

$ 7,576,000

Revenues

1,394,000

7,344,000

5,942,000

Required notice period for voluntary termination of collaborative agreement

90 days

90 days

Royalty rate as a percentage of net sales, tier 1

7.00%

Level of net sales at which royalty rate changes to tier 2

$ 25,000,000

Royalty rate as a percentage of net sales, tier 2

14.00%

Royalty rate of savings from improvement

33.00%

Maximum milestone payments required upon successful achievement, first product

$ 30,000,000

Maximum milestone payments required upon successful achievement, per each additional product

30,000,000

Maximum milestone payments required for certain sales milestones, per product

$ 22,500,000

Thrive Agrobiotics, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 1,667,000

Required notice period for voluntary termination of collaborative agreement

90 days

Thrive Agrobiotics, Inc. | Maximum | Collaborations and licenses

Collaboration Agreements [Line Items]

Milestone payments required upon successful achievement, per product

$ 5,500,000

Persea Bio, LLC | Collaborations and licenses

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 5,000,000

Revenues

955,000

946,000

$ 1,278,000

Required notice period for voluntary termination of collaborative agreement

90 days

AquaBounty Technologies, Inc. | Collaborations and licenses

Collaboration Agreements [Line Items]

Royalty rate as a percentage of gross profit

16.66%

ZIOPHARM Oncology, Inc. | Preferred stock

Collaboration Agreements [Line Items]

Fair value of assets

160,832,000

160,832,000

$ 158,376,000

Oragenics, Inc.

Collaboration Agreements [Line Items]

Conversion of promissory note into common stock (in shares) | shares

338,100

Oragenics, Inc. | Preferred stock

Collaboration Agreements [Line Items]

Fair value of assets

$ 0

$ 0

$ 0

$ 0

Intrexon T1D Partners, LLC

Collaboration Agreements [Line Items]

Deferred revenue

$ 8,517,000

Reacquisition of in-process research and development

$ 10,453,000

Shares issued in asset acquisition or for reacquired in-process research and development, shares | shares

1,933,737

Shares issued in asset acquisition or for reacquired in-process research and development

$ 18,970,000

Ownership interest

100.00%

Genten Therapeutics, Inc.

Collaboration Agreements [Line Items]

Ownership interest

100.00%

CRS Bio, Inc.

Collaboration Agreements [Line Items]

Ownership interest

100.00%

Relieve Genetics, Inc.

Collaboration Agreements [Line Items]

Ownership interest

100.00%

Exotech Bio, Inc.

Collaboration Agreements [Line Items]

Ownership interest

49.00%

Short-term Investments - Summar

Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 119,749	$ 6,275
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(61)	(2)
Aggregate Fair Value	119,688	6,273
United States government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	119,401	6,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(61)	(2)
Aggregate Fair Value	119,340	5,998
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	348	275
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 348	$ 275

Investments in Preferred Stoc_2

Investments in Preferred Stock - Additional Information (Details)	May 25, 2018	Nov. 30, 2017USD ($)	Mar. 31, 2017USD ($)shares	Jun. 30, 2016$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Sep. 30, 2018USD ($)
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					$ 122,181,000	$ 183,173,000
Noncash dividend income on preferred shares					14,841,000	16,756,000	$ 7,421,000
Purchase of preferred stock					0	1,161,000	2,308,000
Receivables converted to preferred stock					$ 0	$ 3,385,000	$ 0
Fibrocell Science, Inc.
Schedule of Investments [Line Items]
Convertible preferred shares, shares issued | shares			1,161
Number of common shares into which warrants are convertible (in shares) | shares			99,769
Stockholders' equity, reverse stock split	1-for-5
Stockholders' equity reverse stock split conversion ratio	0.2
Preferred stock, dividend rate, percentage					4.00%
ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Preferred shares, stated value (in usd per share) | $ / shares				$ 1,200
Preferred shares, dividend rate (in usd per share) | $ / shares					$ 12
ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Dividend income, number of preferred shares received (in shares) | shares					11,415	13,460	6,184
Noncash dividend income on preferred shares					$ 14,793,000	$ 16,717,000	$ 7,421,000
Fibrocell Science, Inc.
Schedule of Investments [Line Items]
Purchase of preferred stock			$ 1,161,000
Preferred stock | ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis						160,832,000		$ 158,376,000
Preferred stock | Oragenics, Inc.
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					$ 0	0
Receivables converted to preferred stock		$ 3,385,000
Preferred stock, initial dividend rate					12.00%
Preferred stock, subsequent dividend rate					20.00%
Preferred stock | Fibrocell Science, Inc.
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					$ 191,000	$ 393,000
ZIOPHARM Oncology, Inc. | Collaborations and licenses
Schedule of Investments [Line Items]
Collaborative arrangement consideration received, number of preferred shares (in shares) | shares				100,000

Investments in Preferred Stoc_3

Investments in Preferred Stock - Schedule of Changes in Level 3 Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Purchase of preferred stock	$ 0	$ 1,161	$ 2,308
Conversion of receivables to preferred stock	0	3,385	0
Dividend income from investments in preferred stock	14,841	16,756	7,421
Significant Unobservable Inputs (Level 3)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	161,225	129,545
Purchase of preferred stock	0	766
Conversion of receivables to preferred stock	0	3,385
Dividend income from investments in preferred stock	14,841	16,756
Net unrealized appreciation (depreciation) in the fair value of the investments in preferred stock	(17,499)	10,773
Return of preferred stock	(158,376)	0
Ending balance	$ 191	$ 161,225	$ 129,545

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	$ 119,340	$ 5,998
Other	468	850
Fair value of assets	122,181	183,173
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	0	0
Other	0	0
Fair value of assets	1,626	10,537
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	119,340	5,998
Other	468	850
Fair value of assets	120,364	11,411
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	0	0
Other	0	0
Fair value of assets	191	161,225
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	2,182	15,100
Common Stock | Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	1,626	10,537
Common Stock | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	556	4,563
Common Stock | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Preferred stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	191	161,225
Preferred stock | Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Preferred stock | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Preferred stock | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	$ 191	$ 161,225

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jul. 31, 2018	Dec. 31, 2017
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liabilities measured at fair value on a recurring basis	$ 585		$ 585
3.5% Convertible Notes Due 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of convertible debt	141,000
Carrying value of convertible debt	$ 148,101	$ 143,723

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Changes in Level 3 Liabilities (Details) - Significant Unobservable Inputs (Level 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 585	$ 2,081
Acquisition date fair value of contingent consideration liability	0	585
Change in fair value of contingent consideration recognized in selling, general and administrative expenses	0	(2,081)
Ending Balance	$ 585	$ 585

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Inventory	$ 21,447	$ 20,493
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	4,729	2,673
Work in process
Inventory [Line Items]
Inventory	4,391	4,767
Livestock
Inventory [Line Items]
Inventory	10,167	11,040
Feed
Inventory [Line Items]
Inventory	$ 2,160	$ 2,013

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 12,490	$ 11,767
Buildings and building improvements	20,371	18,183
Furniture and fixtures	1,891	2,515
Equipment	74,555	65,863
Leasehold improvements	28,289	25,277
Breeding stock	4,582	3,832
Computer hardware and software	11,697	10,128
Trees	11,910	6,642
Construction and other assets in progress	18,880	14,113
Property, plant and equipment, gross	184,665	158,320
Less: Accumulated depreciation and amortization	(55,791)	(45,646)
Property, plant and equipment, net	$ 128,874	$ 112,674

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Cash paid in asset acquisition	$ (15,500)	$ 14,219	$ 7,244
Depreciation expense	14,328	$ 11,951	$ 9,387
Facility Closing
Property, Plant and Equipment [Line Items]
Loss on disposition of property, plant and equipment	$ 5,057

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill impairment charge		$ 0	$ 13,823
Accumulated goodwill impairment losses	$ 13,823	13,823
Indefinite-lived intangible asset impairment charge		2,950
Loss on abandonment of assets		20,928	3,124	$ 666
Amortization expense		18,784	$ 19,194	$ 15,185
AquaBounty Technologies, Inc.
Goodwill [Line Items]
Goodwill impairment charge		$ 13,001
Patents, developed technologies and know-how
Goodwill [Line Items]
Finite-lived intangible asset impairment charge	60,504
Loss on abandonment of assets	$ 16,027

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill
Beginning Balance	$ 153,289	$ 157,175
Acquisitions	0	4,850
Impairment	0	(13,823)
Foreign currency translation adjustments	(3,704)	5,087
Ending Balance	$ 149,585	$ 153,289

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	$ (46,039)	$ (53,904)
Net	123,943
Intangible Assets [Abstract]
Gross Carrying Amount	175,330	286,781
Net	129,291	232,877
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	152,482	263,615
Accumulated Amortization	(35,133)	(44,954)
Net	117,349	218,661
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	10,700	10,700
Accumulated Amortization	(7,565)	(6,383)
Net	3,135	4,317
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	6,800	6,800
Accumulated Amortization	(3,341)	(2,567)
Net	$ 3,459	4,233
Weighted Average | Patents, developed technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	15 years 6 months
Weighted Average | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	6 years 6 months
Weighted Average | Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	9 years 3 months 18 days
In-process research and development
Finite-Lived Intangible Assets, Net [Abstract]
Indefinite-lived intangible assets	$ 5,348	$ 5,666

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,019	$ 11,966
2,020	11,863
2,021	11,675
2,022	10,676
2,023	9,798
Thereafter	67,965
Net	$ 123,943

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Credit Facility	12 Months Ended
	Dec. 31, 2018USD ($)
Trans Ova Genetics, LC | First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Line of credit facility, interest rate at period end	5.30%
Line of credit outstanding	$ 0
Trans Ova Genetics, LC | First National Bank of Omaha | London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	2.95%
Exemplar Genetics, LLC | American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	5.75%
Line of credit outstanding	$ 466,000
Minimum | Trans Ova Genetics, LC | First National Bank of Omaha
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Long-term debt	$ 211,794	$ 8,037
Less current portion	559	502
Long-term debt, less current portion	211,235	7,535
Convertible debt
Debt Instrument [Line Items]
Long-term debt	203,391	0
Notes payable
Debt Instrument [Line Items]
Long-term debt	4,551	5,010
Royalty-based financing
Debt Instrument [Line Items]
Long-term debt	2,085	2,132
Other
Debt Instrument [Line Items]
Long-term debt	$ 1,767	$ 895

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended			12 Months Ended
	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 31, 2018USD ($)day$ / shares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Mar. 31, 2013USD ($)
Debt Instrument [Line Items]
Proceeds from long-term debt, net of issuance costs				$ 219,859,000	$ 325,000	$ 547,000
Equity component of convertible debt, net of issuance costs and deferred taxes				36,868,000
Deferred income taxes				21,278,000	2,528,000	3,467,000
Accretion of debt discount and amortization of deferred financing costs				4,378,000	0	0
Long-term debt issued to a related party in an asset acquisition				30,000,000	0	0
Interest expense				8,530,000	611,000	$ 861,000
Long-term debt	$ 211,794,000			211,794,000	8,037,000
Convertible debt
Debt Instrument [Line Items]
Long-term debt	203,391,000			203,391,000	0
Convertible debt | ActoBio Therapeutics Inc. | Harvest Intrexon Enterprise Fund I, LP
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.00%
Interest expense				290,000
Long-term debt	$ 30,290,000			$ 30,290,000
Notes payable to banks | Trans Ova Genetics, LC | American State Bank
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	3.95%			3.95%
Long-term debt	$ 4,482,000			$ 4,482,000
Debt instrument, periodic payment				39,000
Royalty-based financing
Debt Instrument [Line Items]
Long-term debt	2,085,000			2,085,000	$ 2,132,000
Royalty-based financing | AquaBounty Technologies, Inc. | Atlantic Canada Opportunities Agency
Debt Instrument [Line Items]
Long-term debt	2,085,000			2,085,000
Amount available under the grant for research and development	2,107,000			$ 2,107,000
Claims period				5 years
Royalty on products				10.00%
Amount claimed							$ 1,952,000
Long-term debt, fair value at date of business combination							1,107,000
Accreted difference between face value of amount drawn and acquisition date fair value							$ 845,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount	200,000,000		$ 200,000,000	$ 200,000,000
Proceeds from long-term debt, net of issuance costs			193,958,000
Debt issuance costs			$ 6,042,000
Debt instrument, interest rate, stated percentage			3.50%
Conversion rate			58.6622
Principal amount used in conversion			$ 1,000
Conversion price (in usd per share) | $ / shares			$ 17.05
Debt instrument redemption price, percentage			100.00%
Carrying value of convertible debt	$ 148,101,000		$ 143,723,000	$ 148,101,000
Equity component of convertible debt, net of issuance costs and deferred taxes			50,235,000
Deferred income taxes			$ 13,367,000
Effective interest rate on convertible notes	11.02%			11.02%
Convertible notes, unamortized discount and issuance costs	$ 51,899,000			$ 51,899,000
Total interest expense				7,840,000
Interest expense paid in cash				3,462,000
Accretion of debt discount and amortization of deferred financing costs				4,378,000
3.5% Convertible Notes Due 2023 | Minimum
Debt Instrument [Line Items]
Common stock price trading days | day			20
Common stock price consecutive trading days | day			30
Percentage of common share price over conversion price for conversion			130.00%
3.5% Convertible Notes Due 2023 | Maximum
Debt Instrument [Line Items]
Common stock price trading days | day			5
Common stock price consecutive trading days | day			5
Debt instrument redemption price, percentage			98.00%
Merck Convertible Note
Debt Instrument [Line Items]
Aggregate principal amount	$ 25,000,000			$ 25,000,000
Percentage of IPO price used upon conversion	0.9
PIK interest rate if converted to subsidiary equity	0.05			0.05
Harvest Intrexon Enterprise Fund I, LP | ActoBio Therapeutics Inc.
Debt Instrument [Line Items]
Long-term debt issued to a related party in an asset acquisition		$ 30,000,000

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands	Dec. 31, 2018USD ($)
Debt Disclosure [Abstract]
2,019	$ 559
2,020	30,843
2,021	25,405
2,022	420
2,023	201,442
Thereafter	2,939
Total	$ 261,608

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Loss before income taxes	$ (536,234)	$ (129,700)	$ (194,151)
Domestic
Income Tax [Line Items]
Loss before income taxes	(443,337)	(71,343)	(157,067)
Foreign
Income Tax [Line Items]
Loss before income taxes	$ (92,897)	$ (58,357)	$ (37,084)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
United States federal income taxes:
Current	$ (31)	$ 27	$ (17)
Deferred	(11,855)	(523)	1,396
Foreign income taxes:
Current	(332)	(379)	(393)
Deferred	(5,068)	(2,269)	(5,177)
State income taxes:
Current	113	0	0
Deferred	(4,355)	264	314
Total income tax benefit	$ (21,528)	$ (2,880)	$ (3,877)

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Federal corporate income tax rate	21.00%		34.00%
Computed statutory income tax benefit	$ (112,609)	$ (44,098)	$ (66,011)
State and provincial income tax benefit, net of federal income taxes	(24,724)	(3,294)	(7,905)
Nondeductible stock based compensation	1,834	4,147	3,321
Nondeductible officer compensation	294	476	0
Gain on dividend distribution of AquaBounty common stock	0	3,965	0
Impairment of goodwill	0	4,700	0
Research and development tax incentives	(1,088)	(1,166)	(6,350)
Acquisition and internal restructuring transaction costs	52	354	571
Provisional impact of the Tax Act	0	85,288	0
Enacted changes in foreign tax rates and foreign tax reforms	0	2,138	0
Reacquired in-process research and development	2,696	0	0
Change in deferred state tax rate	8,666	0	0
United States-foreign rate differential	3,017	5,410	3,463
Other, net	(486)	(64)	1,485
Income tax reconciliation income tax benefit before valuation allowance, total	(122,348)	57,856	(71,426)
Change in valuation allowance for deferred tax assets	100,820	(60,736)	67,549
Total income tax benefit	$ (21,528)	$ (2,880)	$ (3,877)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets
Allowance for doubtful accounts	$ 1,490	$ 1,300
Inventory	614	489
Equity securities and investments in affiliates	30,241	17,510
Intangible assets	71,205	0
Accrued liabilities	4,412	3,131
Stock-based compensation	29,297	26,936
Deferred revenue	16,297	61,785
Research and development tax credits	11,597	11,385
Net operating and capital loss carryforwards	148,411	111,453
Total deferred tax assets	313,564	233,989
Less: Valuation allowance	308,113	215,582	$ 256,165	$ 190,174
Net deferred tax assets	5,451	18,407
Deferred tax liabilities
Property, plant and equipment	528	237
Intangible assets	0	33,790
Long-term debt	12,136	0
Total deferred tax liabilities	12,664	34,027
Net deferred tax liabilities	$ (7,213)	$ (15,620)

Income Taxes - Summary of Valua

Income Taxes - Summary of Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Valuation Allowance
Valuation allowance at beginning of year	$ 215,582	$ 256,165	$ 190,174
Mergers and acquisitions, net	418	0	(1,416)
Current year operations	122,853	26,619	67,549
Adoption of new accounting pronouncements	(7,477)	17,843	0
Provisional impact of the Tax Act	0	(87,473)	0
Equity component of long-term debt	(13,367)	0	0
Change in deferred state tax rate	(8,666)	0	0
Changes in foreign tax rates and foreign tax reforms	0	1,327	0
Foreign currency translation adjustment	(1,230)	1,101	(142)
Valuation allowance at end of year	$ 308,113	$ 215,582	$ 256,165

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Federal and state research and development tax credits	$ 11,597	$ 11,385
Accumulated deficit	$ (1,330,545)	(847,820)
Estimated tax benefit upon enactment of Tax Act		2,185
Change in deferred tax assets resulting from enactment of Tax Act		87,473
Estimated tax benefit due to changes in deferred tax liabilities upon enactment of Tax Act		1,730
Estimated current tax benefit upon enactment of Tax Act		455
Provisional transition tax amount		0
AquaBounty Technologies, Inc.
Operating Loss Carryforwards [Line Items]
Expiration date of Federal income tax loss carryforwards	2,018
Ownership percentage in AquaBounty (more than)			50.00%
Annual usage limit of operating loss carryforwards	$ 900
Foreign Subsidiaries
Operating Loss Carryforwards [Line Items]
Accumulated deficit	150,409
Domestic
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition	41,909
Operating loss carryforwards	369,102
Federal and state research and development tax credits	$ 7,881
Expiration date of Federal income tax loss carryforwards	2,022
Domestic | GenVec, Inc.
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition	$ 13,376
Domestic | AquaBounty Technologies, Inc.
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	37,807
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	159,811
Foreign | AquaBounty Technologies, Inc.
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	14,007
Tax credit	2,628
BELGIUM
Operating Loss Carryforwards [Line Items]
Additional deferred tax liabilities recorded due to enacted foreign tax changes		$ 2,307
Generated after 2017 | Domestic
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	116,600
Generated after 2017 | Domestic | AquaBounty Technologies, Inc.
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 9,370

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Jan. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2018
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares		6,900,000	1,207,980
Value of shares issued in public or private offerings		$ 82,374	$ 13,686		$ 87,990	$ 13,686
Shares issued in share lending agreement, shares							7,479,431
Underwriting discounts and commissions		3,688
Capitalized offering expenses		$ 188
Shares issued, price per share							$ 13.37
Shares issued for exercises of warrants					$ 2,336
Noncash dividend to shareholders						$ 0
Affiliates Of Third Security
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares		1,000,000
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Noncash dividend, shares				1,776,557
Noncash dividend to shareholders				$ 22,385
Intrexon Equity Plans
Class of Stock [Line Items]
Adjustment due to dividend (in shares)						46,766
Adjustment due to dividend (in usd per share)						$ 31.11
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Value of shares issued in public or private offerings		$ 10,616
Shares issued for exercises of warrants	$ 4,316
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Additional investment in subsidiary	$ 3,077	$ 5,000		$ 25,000

Shareholders' Equity - Componen

Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ 362,855	$ 533,631
Unrealized loss on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	(61)	(2)
Loss on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	(28,551)	(15,552)
Total accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ (28,612)	$ (15,554)

Share-Based Payments - Schedule

Share-Based Payments - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 36,296	$ 41,576	$ 42,202
Cost of products
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	78	116	81
Cost of services
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	237	322	274
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	9,676	9,336	9,251
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 26,305	$ 31,802	$ 32,596

Share-Based Payments - Addition

Share-Based Payments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services	$ 10,695	$ 11,118	$ 10,777
Intrexon Equity Plan - 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	0
Options outstanding (in shares)	410,909
Intrexon Equity Plan - 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	5,086,700
Options outstanding (in shares)	10,682,154
Number of authorized awards (in shares)	20,000,000
Restricted stock units outstanding (in shares)	970,341	0
Unrecognized compensation costs related to restricted stock unit awards	$ 9,641
Intrexon Equity Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	11,093,063	11,382,747	11,640,383		11,043,528
Term at issuance of option	10 years
Vesting period of option	4 years
Unrecognized compensation costs related to unvested stock option awards	$ 37,353
Weighted average grant date fair value of options granted (in usd per share)	$ 7.94	$ 12.19	$ 16.28
Aggregate intrinsic value of options exercised	$ 356	$ 2,429	$ 22,704
Options outstanding, weighted average exercise price (in usd per share)	$ 27.95	$ 28.99	$ 31.25		$ 32.66
Options exercisable (in shares)	7,002,519
Aqua Bounty 2006 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)				0
Aqua Bounty Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	339,964	227,203
Options outstanding, weighted average exercise price (in usd per share)	$ 7.09	$ 9.39
Options exercisable (in shares)	303,986	192,748
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly base salary	$ 200
Lock-up period	3 years
Selling, general and administrative | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services	$ 1,956	$ 1,908	$ 1,861
Options | Intrexon Equity Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized over weighted-average period	2 years
Restricted stock units | Intrexon Equity Plan - 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized over weighted-average period	3 years

Share-Based Payments - Intrexon

Share-Based Payments - Intrexon Equity Plans - Schedule of Stock Option Activity (Details) - Intrexon Equity Plans - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares
Balances at beginning of period (in shares)	11,382,747	11,640,383	11,043,528
Granted (in shares)	1,470,339	3,920,950	4,644,860
Adjustment due to dividend (in shares)		46,766
Exercised (in shares)	(45,159)	(149,429)	(1,210,840)
Forfeited (in shares)	(929,596)	(3,797,105)	(2,760,809)
Expired (in shares)	(785,268)	(278,818)	(76,356)
Balances at period end (in shares)	11,093,063	11,382,747	11,640,383	11,043,528
Weighted Average Exercise Price (usd per share)
Balances at beginning of period (in usd per share)	$ 28.99	$ 31.25	$ 32.66
Granted (in usd per share)	14.26	21.47	29.39
Adjustment due to dividend (in usd per share)		31.11
Exercised (in usd per share)	(6.59)	(6.37)	(15.83)
Forfeited (in usd per share)	(21.48)	(28.37)	(40.34)
Expired (in usd per share)	(26.25)	(33.18)	(37.81)
Balances at period end (in usd per share)	$ 27.95	28.99	$ 31.25	$ 32.66
Additional Disclosures
Exercisable at period end (in shares)	7,002,519
Options exercisable, weighted average exercise price (in usd per share)	$ 30.37	$ 29.96
Balances at period end, weighted average remaining contractual period	6 years 9 months 21 days	7 years 3 months 25 days	8 years 2 months 15 days	8 years 5 months 27 days
Exercisable at period end, weighted average remaining contractual period	5 years 11 months 20 days

Share-Based Payments - Intrex_2

Share-Based Payments - Intrexon Equity Plans - Summary of Information About Stock Options Outstanding (Details) - Intrexon Equity Plans - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding, number of options (in shares)	11,093,063	11,382,747
Options outstanding, weighted average exercise price (in usd per share)	$ 27.95	$ 28.99	$ 31.25	$ 32.66
Options outstanding, weighted average remaining life (in years)	6 years 9 months 21 days	7 years 3 months 25 days
Options outstanding, aggregate intrinsic value	$ 169	$ 2,020
Options exercisable, number of options (in shares)	7,002,519	5,306,697
Options exercisable, weighted average exercise price (in usd per share)	$ 30.37	$ 29.96
Options exercisable, weighted average remaining life (in years)	5 years 11 months 20 days	6 years 1 month 20 days
Options exercisable, aggregate intrinsic value	$ 169	$ 2,020
Price range 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 3.17	$ 2.64
Stock options, exercise price range, upper limit (in usd per share)	$ 19.52	$ 9.30
Options outstanding, number of options (in shares)	1,973,818	453,371
Options outstanding, weighted average exercise price (in usd per share)	$ 13.70	$ 7.06
Options outstanding, weighted average remaining life (in years)	7 years 6 months 13 days	3 years 11 months 10 days
Options outstanding, aggregate intrinsic value	$ 169	$ 2,020
Options exercisable, number of options (in shares)	833,007	453,371
Options exercisable, weighted average exercise price (in usd per share)	$ 12.80	$ 7.06
Options exercisable, weighted average remaining life (in years)	4 years 10 months 7 days	3 years 11 months 10 days
Options exercisable, aggregate intrinsic value	$ 169	$ 2,020
Price range 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 19.85	$ 12.50
Stock options, exercise price range, upper limit (in usd per share)	$ 20.94	$ 21.38
Options outstanding, number of options (in shares)	1,914,763	3,158,121
Options outstanding, weighted average exercise price (in usd per share)	$ 20.93	$ 20.58
Options outstanding, weighted average remaining life (in years)	7 years 11 months 25 days	8 years 8 months 25 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	500,263	456,942
Options exercisable, weighted average exercise price (in usd per share)	$ 20.92	$ 19.52
Options exercisable, weighted average remaining life (in years)	7 years 7 months 30 days	7 years 1 month 18 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 21	$ 21.43
Stock options, exercise price range, upper limit (in usd per share)	$ 27.08	$ 28.81
Options outstanding, number of options (in shares)	2,057,126	3,399,721
Options outstanding, weighted average exercise price (in usd per share)	$ 23.29	$ 25.55
Options outstanding, weighted average remaining life (in years)	7 years 2 months 35 days	6 years 10 months 28 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	1,248,370	1,804,401
Options exercisable, weighted average exercise price (in usd per share)	$ 23.01	$ 25.86
Options exercisable, weighted average remaining life (in years)	6 years 7 months 38 days	5 years 7 months 38 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 27.10	$ 28.88
Stock options, exercise price range, upper limit (in usd per share)	$ 29.56	$ 40.99
Options outstanding, number of options (in shares)	2,666,109	2,751,716
Options outstanding, weighted average exercise price (in usd per share)	$ 29.19	$ 32.07
Options outstanding, weighted average remaining life (in years)	5 years 2 months 40 days	6 years 8 months 12 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	2,593,151	1,732,250
Options exercisable, weighted average exercise price (in usd per share)	$ 29.20	$ 31.51
Options exercisable, weighted average remaining life (in years)	5 years 2 months 23 days	6 years 3 months 25 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 29.58	$ 41.41
Stock options, exercise price range, upper limit (in usd per share)	$ 65.08	$ 65.08
Options outstanding, number of options (in shares)	2,481,247	1,619,818
Options outstanding, weighted average exercise price (in usd per share)	$ 47.24	$ 53.52
Options outstanding, weighted average remaining life (in years)	6 years 6 months 32 days	7 years 5 months 2 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	1,827,728	859,733
Options exercisable, weighted average exercise price (in usd per share)	$ 47.65	$ 53.07
Options exercisable, weighted average remaining life (in years)	6 years 6 months 15 days	7 years 4 months 18 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0

Share-Based Payments - Intrex_3

Share-Based Payments - Intrexon Equity Plans - Schedule of Restricted Stock Unit Activity (Details) - Intrexon Equity Plan - 2013 Plan - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Restricted Stock Units
Balances at beginning of period (in shares)	0
Granted (in shares)	1,069,126
Vested (in shares)	(25,000)
Forfeited (in shares)	(73,785)
Balances at period end (in shares)	970,341	0
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 0
Granted (in usd per share)	13.84
Vested (in usd per share)	(15.82)
Forfeited (in usd per share)	(13.47)
Balances at period end (in usd per share)	$ 13.82	$ 0
Additional Disclosures
Balances at period end, weighted average remaining contractual period	1 year 5 months 5 days	0 years

Commitments and Contingencies -

Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 9,182
2,020	9,910
2,021	9,127
2,022	8,305
2,023	7,229
Thereafter	34,157
Future minimum lease payments under operating leases, total	$ 77,910

Commitments and Contingencies_2

Commitments and Contingencies - Operating Leases - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Rent expense, including other facility expenses	$ 13,076	$ 11,064	$ 8,593

Commitments and Contingencies_3

Commitments and Contingencies - Purchase Commitments - Additional Information (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
Outstanding contractual purchase commitments	$ 20,055

Commitments and Contingencies_4

Commitments and Contingencies - Contingencies - Additional Information (Details) - Licensing and patent infringement suit $ in Thousands	1 Months Ended	12 Months Ended		50 Months Ended
	Apr. 30, 2016USD ($)	Dec. 31, 2018claim	Dec. 31, 2016USD ($)	Apr. 30, 2016USD ($)
Loss Contingencies [Line Items]
Damages awarded to TransOva	$ 528
Cumulative payments for royalties				$ 3,170
Royalty payments not yet deposited	2,759			$ 2,759
XY, LLC
Loss Contingencies [Line Items]
Damages awarded against TransOva	$ 6,066
Claims dismissed | claim		10
Total claims | claim		12
Claims pending resolution | claim		2
Selling, general and administrative
Loss Contingencies [Line Items]
Litigation settlement expense			$ 4,228

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	1 Months Ended					10 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Nov. 30, 2015	Jul. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Oct. 31, 2017
Related Party Transaction [Line Items]
Shares issued as payment for services							$ 10,695,000	$ 11,118,000	$ 10,777,000
Shares issued during the period	6,900,000	1,207,980
Revenues							160,574,000	230,981,000	190,926,000
Purchases of property and equipment							41,587,000	46,666,000	31,629,000
Fair value of assets		$ 183,173,000					122,181,000	183,173,000
Other nonoperating income							630,000	1,013,000	1,700,000
Third Security
Related Party Transaction [Line Items]
Expense for services							$ 47,000	$ 409,000	$ 309,000
Services agreement, term					1 year
Shares issued as payment for services, shares							696,033	500,650	337,163
Shares issued as payment for services							$ 8,324,000	$ 8,704,000	$ 8,571,000
Sublease rental income							89,000	43,000	43,000
Affiliates Of Third Security
Related Party Transaction [Line Items]
Shares issued during the period	1,000,000
Intrexon Energy Partners, LLC
Related Party Transaction [Line Items]
Purchases of property and equipment		2,812,000
Oragenics, Inc.
Related Party Transaction [Line Items]
Common stock purchased from collaborative partners, shares				226,142
Price per share of common shares (in usd per share)				$ 5.20
Harvest Intrexon Enterprise Fund I, LP
Related Party Transaction [Line Items]
Other nonoperating income								1,839,000	2,483,000
Series A Preferred Shares
Related Party Transaction [Line Items]
Shares issued during the period						0
Series A Preferred Shares | Affiliates Of Third Security
Related Party Transaction [Line Items]
Convertible preferred stock, amount authorized										$ 100,000,000
Common Stock | Third Security
Related Party Transaction [Line Items]
Expense for services					$ 800,000
Other assets | Convertible note and warrants | Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Fair value of assets		$ 575,000					$ 120,000	575,000
Third Security | Chief Executive Officer
Related Party Transaction [Line Items]
Ownership interest							100.00%
AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Realized investment (gain) loss			$ 4,098,000
Collaborations and licenses
Related Party Transaction [Line Items]
Revenues							$ 76,869,000	$ 145,579,000	$ 109,871,000
Collaborations and licenses | Histogenics Corporation, OvaScience Inc., and Synthetic Biologics Inc.
Related Party Transaction [Line Items]
Revenues							$ 11,877,000

Net Loss per Share - Computatio

Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2018	[1]	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	[2]	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net loss attributable to Intrexon	$ (340,465)		$ (57,324)	$ (65,382)	$ (46,165)	$ (27,266)		$ (39,689)	$ (18,664)	$ (31,399)	$ (509,336)	$ (117,018)	$ (186,612)
Denominator:
Weighted average shares outstanding, basic and diluted (in shares)											129,521,731	119,998,826	117,983,836
Net loss attributable to Intrexon per share, basic and diluted (in usd per share)	$ (2.59)		$ (0.44)	$ (0.51)	$ (0.36)	$ (0.23)		$ (0.33)	$ (0.16)	$ (0.26)	$ (3.93)	$ (0.98)	$ (1.58)
[1]	During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17).
[2]	During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Net Loss per Share - Potentiall

Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	31,152,336	11,516,011	11,640,383
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	18,955,668	0	0
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	11,093,063	11,382,747	11,640,383
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	970,341	0	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	133,264	133,264	0

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2018	[1]	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	[2]	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 43,185		$ 32,448	$ 45,275	$ 39,666	$ 77,028		$ 46,016	$ 54,433	$ 53,504
Operating loss	(336,882)		(66,471)	(49,735)	(52,522)	(26,492)		(44,747)	(35,270)	(31,381)	$ (505,610)	$ (137,890)	$ (125,166)
Net loss	(341,722)		(58,746)	(66,829)	(47,409)	(33,945)		(40,836)	(19,662)	(32,377)	(514,706)	(126,820)	(190,274)
Net loss attributable to Intrexon	$ (340,465)		$ (57,324)	$ (65,382)	$ (46,165)	$ (27,266)		$ (39,689)	$ (18,664)	$ (31,399)	$ (509,336)	$ (117,018)	$ (186,612)
Net loss attributable to Intrexon per share, basic and diluted (in usd per share)	$ (2.59)		$ (0.44)	$ (0.51)	$ (0.36)	$ (0.23)		$ (0.33)	$ (0.16)	$ (0.26)	$ (3.93)	$ (0.98)	$ (1.58)
[1]	During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 4 and 5). The Company also recorded an intangible asset impairment charge and a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 17).
[2]	During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Defined Contribution Plans - Ad

Defined Contribution Plans - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Retirement Benefits [Abstract]
Defined contribution plans, cost recognized	$ 2,493	$ 2,367	$ 1,857